

 



<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
  "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml"
      xmlns:foaf="http://xmlns.com/foaf/0.1/"
      xmlns:dc="http://purl.org/dc/terms/"
      xmlns:doi="http://dx.doi.org/"
      xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
      xmlns:xsd="http://www.w3.org/2001/XMLSchema-datatypes#"
      lang="en" xml:lang="en"
      itemscope itemtype="http://schema.org/Article"
      class="no-js">
<head prefix="og: http://ogp.me/ns#">
  <title>PLOS ONE: Molecular Analysis of Thymopentin Binding to HLA-DR Molecules</title>


<link rel="stylesheet" type="text/css"  href="/css/global-min.css?v=izteQ6tu7kgsJZW_xmrYizvKiHM" />


    <!--[if lte IE 7]>
<link rel="stylesheet" type="text/css"  href="/css/lte_ie7-min.css?v=3bykQUyQmReeuobVyPozcJ9LxRc" />
    <![endif]-->


<link rel="stylesheet" type="text/css"  href="/css/jquery-ui-min.css?v=eXDHTEJM0lIAmDe5k0I0Ad4nxNo" />


<link rel="stylesheet" type="text/css"  href="/css/journal.css?v=T7ZVxJfgk9jNxLAJ2qHz1vZpgYU" />


<link rel="stylesheet" type="text/css" media="print" href="/css/print-min.css?v=T5lb0B3q6EXBsuDluc5V5w+AkRc" />


  <link rel="stylesheet" href="http://f.fontdeck.com/s/css/js/www.plosone.org/24557.css" type="text/css"/>

  <!--chartbeat -->
  <script type="text/javascript">var _sf_startpt = (new Date()).getTime()</script>
  <script>document.documentElement.className += ' js';</script>

  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <meta http-equiv="X-UA-Compatible" content="IE=EmulateIE7; IE=EmulateIE9"/>
  <meta name="description" content="PLOS ONE: an inclusive, peer-reviewed, open-access resource from the PUBLIC LIBRARY OF SCIENCE. Reports of well-performed scientific studies from all disciplines freely available to the whole world."/>
  <meta name="keywords" content="PLOS, Public Library of Science, Open Access, Open-Access, Science, Medicine, Biology, Research, Peer-review, Inclusive, Interdisciplinary, Ante-disciplinary, Physics, Chemistry, Engineering"/>
  <meta name="almHost" content="http://alm.plos.org/api/v3/articles"/>
  <meta name="searchHost" content="http://api.plos.org/search" />
  <meta name="termsHost" content="http://api.plos.org/terms" />
  <meta name="solrApiKey" content="plos"/>
  <meta name="almAPIKey" content="3pezRBRXdyzYW6ztfwft" />
  <meta name="currentJournal" content="PLoSONE" />
  <meta name="almRequestBatchSize" content="" />

  <meta name="citation_publisher" content="Public Library of Science"/>
  <meta name="citation_doi" content="10.1371/journal.pone.0001348"/>
  <meta name="dc.identifier" content="10.1371/journal.pone.0001348" />

    <meta name="citation_title" content="Molecular Analysis of Thymopentin Binding to HLA-DR Molecules"/>
    <meta itemprop="name" content="Molecular Analysis of Thymopentin Binding to HLA-DR Molecules"/>

      <meta name="citation_author" content="Zuojia Liu"/>
            <meta name="citation_author_institution" content="State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China"/>
      <meta name="citation_author" content="Xiliang Zheng"/>
            <meta name="citation_author_institution" content="State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China"/>
      <meta name="citation_author" content="Jin Wang"/>
            <meta name="citation_author_institution" content="State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China"/>
            <meta name="citation_author_institution" content="Department of Chemistry and Physics, State University of New York, Stony Brook, New York, United States of America"/>
      <meta name="citation_author" content="Erkang Wang"/>
            <meta name="citation_author_institution" content="State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China"/>

    <meta name="citation_date" content="2007/12/26"/>

  <meta name="citation_pdf_url" content="http://dx.plos.org/10.1371/journal.pone.0001348.pdf" />

      <meta name="citation_journal_title" content="PLOS ONE" />
    <meta name="citation_firstpage" content="e1348"/>
    <meta name="citation_issue" content="12"/>
    <meta name="citation_volume" content="2"/>
    <meta name="citation_issn" content="1932-6203"/>

    <meta name="citation_journal_abbrev" content="PLoS ONE" />

      <meta name="citation_reference" content="citation_title=Design of a novel thymopoietin analogue based on conformational analyses.; citation_author=T Solmajer; citation_journal_title=Drugs Des Deliv; citation_volume=6; citation_number=1; citation_pages=213-221; citation_date=1990; " />
      <meta name="citation_reference" content="citation_title=A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin.; citation_author=G Goldstein; citation_author=MP Scheid; citation_author=DH Schlesinger; citation_author=JV Wauwe; citation_journal_title=Science; citation_volume=204; citation_number=2; citation_pages=1309-1310; citation_date=1979; " />
      <meta name="citation_reference" content="citation_title=Thymopentin and splenopentin as immunomodulators, current status.; citation_author=VK Singh; citation_author=S Biswas; citation_author=KB Mathur; citation_author=W Haq; citation_author=SK Garg; citation_journal_title=Immunol Res; citation_volume=17; citation_number=3; citation_pages=345-368; citation_date=1998; " />
      <meta name="citation_reference" content="citation_title=Management of viral infections with thymopentin.; citation_author=E Sundal; citation_author=D Bertelletti; citation_journal_title=Arzneimittel-forsch; citation_volume=44; citation_number=4; citation_pages=866-871; citation_date=1994; " />
      <meta name="citation_reference" content="citation_title=Review of thymic hormones in cancer diagnosis and treatment.; citation_author=B Bodey; citation_author=BJ Bodey; citation_author=SE Siegel; citation_author=HE Kaiser; citation_journal_title=Int J Immunopharmacol; citation_volume=22; citation_number=5; citation_pages=261-73; citation_date=2000; " />
      <meta name="citation_reference" content="citation_title=Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces.; citation_author=B Robert; citation_author=S George; citation_author=H Kevin; citation_author=JB Rothbard; citation_journal_title=Int Immunol; citation_volume=2; citation_number=6; citation_pages=443-451; citation_date=1990; " />
      <meta name="citation_reference" content="citation_title=Abundant empty class II MHC molecules on the surface of immature dendritic cells.; citation_author=L Santambrogio; citation_author=K Aaron; citation_author=FR Sato; citation_author=ME Fischer; citation_author= Dorf; citation_journal_title=Proc Natn Acad Sci U S A; citation_volume=96; citation_number=7; citation_pages=15050-15055; citation_date=1999; " />
      <meta name="citation_reference" content="citation_title=Interaction of peptide antigens and class II major histocompatibility complex antigens.; citation_author=JG Guillet; citation_author=MZ Lai; citation_author=TJ Briner; citation_author=JA Smith; citation_author=ML Gefter; citation_journal_title=Nature; citation_volume=324; citation_number=8; citation_pages=260-262; citation_date=1987; " />
      <meta name="citation_reference" content="citation_title=Processed antigen binds to newly synthesized MHC class II molecules in antigen-specific B lymphocytes.; citation_author=W Haward; citation_author=PA Davidson; citation_author=RA Lazavecchia; citation_author=C Watts; citation_journal_title=Cell; citation_volume=67; citation_number=9; citation_pages=105-116; citation_date=1991; " />
      <meta name="citation_reference" content="citation_title=From peptides to peptidomimetics: design of nonpeptide ligands for major histocompatibility proteins.; citation_author=S Krebs; citation_author=D Rognan; citation_journal_title=Pharm Acta Helv; citation_volume=73; citation_number=10; citation_pages=173-181; citation_date=1998; " />
      <meta name="citation_reference" content="citation_title=MHC Class II expression identifies functionally distinct human regulatory T cells.; citation_author=BA Clare; citation_author=E Wolf; citation_author=DA Hafler; citation_journal_title=J Immunol; citation_volume=176; citation_number=11; citation_pages=4622-4631; citation_date=2006; " />
      <meta name="citation_reference" content="citation_title=Irreversible association of peptide with class II MHC molecules in living cells.; citation_author=AA Lazavecchia; citation_author= Pamela; citation_author=RC Watts; citation_journal_title=Nature; citation_volume=357; citation_number=12; citation_pages=249-251; citation_date=1992; " />
      <meta name="citation_reference" content="citation_title=The relation between major histocompatibility complex (MHC) restriction and the capacity of to bind immunogenic peptides.; citation_author=S Buus; citation_author=A Sette; citation_author=SM Colon; citation_author=C Miles; citation_author=HM Grey; citation_journal_title=Science; citation_volume=235; citation_number=13; citation_pages=1353-1358; citation_date=1987; " />
      <meta name="citation_reference" content="citation_title=Enhanced binding of peptide antigen to purified class II major histocompatibility glycoproteins at acidic pH.; citation_author=PE Jensen; citation_journal_title=J Exp Med; citation_volume=174; citation_number=14; citation_pages=111-1120; citation_date=1991; " />
      <meta name="citation_reference" content="citation_title=Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules.; citation_author=FH Masha; citation_author=JL Strominger; citation_journal_title=J Immun; citation_volume=160; citation_number=15; citation_pages=4386-4397; citation_date=1998; " />
      <meta name="citation_reference" content="citation_title=Inefficient peptide binding by cell-surface class II MHC molecules.; citation_author=MA Sherman; citation_author=DA Weber; citation_author=EA Spotts; citation_author=JC Moore; citation_author=PE Jensen; citation_journal_title=Cell Immuno; citation_volume=182; citation_number=16; citation_pages=1-11; citation_date=1997; " />
      <meta name="citation_reference" content="citation_title=Binding of immunogenic peptides to Ia histocompatibility molecules.; citation_author=BP Babbit; citation_author=PM Allen; citation_author=G Matsueda; citation_author=E Haber; citation_author=ER Unanue; citation_journal_title=Nature; citation_volume=317; citation_number=17; citation_pages=359-361; citation_date=1985; " />
      <meta name="citation_reference" content="citation_title=Binding of photoreactive lysozyme peptides to murine histocompatibility class II molecules.; citation_author=IF Luescher; citation_author=PM Allen; citation_author=ER Unanue; citation_journal_title=Proc Natn Acad Sci U S A; citation_volume=85; citation_number=18; citation_pages=871-874; citation_date=1988; " />
      <meta name="citation_reference" content="citation_title=Regulation of antigen presentation by acidic pH.; citation_author=PE Jensen; citation_journal_title=J Exp Med; citation_volume=171; citation_number=19; citation_pages=779-1784; citation_date=1990; " />
      <meta name="citation_reference" content="citation_title=Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α.; citation_author=F Sallusto; citation_author=A Lanzavecchia; citation_journal_title=J Exp Med; citation_volume=179; citation_number=20; citation_pages=1109-1118; citation_date=1994; " />
      <meta name="citation_reference" content="citation_title=High-affinity fluorescent peptide binding to I-Ad in lipid membranes.; citation_author=TH Watts; citation_author=HM McConneli; citation_journal_title=Proc Natn Acad Sci U S A; citation_volume=83; citation_number=21; citation_pages=9660-9664; citation_date=1986; " />
      <meta name="citation_reference" content="citation_title=Binding of labeled influenza matrix peptide to HLA DR in living B lymphoid cells.; citation_author=R Cepellini; citation_author=G Frumento; citation_author=GB Ferrara; citation_author=T Roberto; citation_author=A Chersi; citation_journal_title=Nature; citation_volume=339; citation_number=22; citation_pages=392-394; citation_date=1989; " />
      <meta name="citation_reference" content="citation_title=Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides.; citation_author=S Theodore; citation_author= Jardetzky; citation_author=H Jeerry; citation_author= Brown; citation_author=C Joan; citation_journal_title=Proc Natn Acad Sci U S A; citation_volume=93; citation_number=23; citation_pages=734-738; citation_date=1996; " />
      <meta name="citation_reference" content="citation_title=Structural basis for major histocompatibility complex (MHC)-like susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris.; citation_author=W Kai; citation_author= Wucherpfennig; citation_author=Y Bei; citation_author=B Kailash; citation_author=S Dimitri; citation_journal_title=Proc Natn Acad Sci U S A; citation_volume=92; citation_number=24; citation_pages=11935-11939; citation_date=1995; " />
      <meta name="citation_reference" content="citation_title=Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function.; citation_author=GM Morris; citation_author=DS Goodsell; citation_author=RS Halliday; citation_author=R Huey; citation_author=WE Hart; citation_journal_title=J Comput Chem; citation_volume=19; citation_number=25; citation_pages=1639-1662; citation_date=1998; " />
      <meta name="citation_reference" content="citation_title=MHC ligands and peptide motifs: first listing.; citation_author=HG Rammensee; citation_author= FriedeT; citation_author=S Stevanovic; citation_journal_title=Immunogenetics; citation_volume=41; citation_number=26; citation_pages=178-228; citation_date=1995; " />
      <meta name="citation_reference" content="citation_title=Antigen processing and presentation to T cells.; citation_author=HM Grey; citation_author=R Chesnut; citation_journal_title=Immunol Today; citation_volume=6; citation_number=27; citation_pages=101-105; citation_date=1985; " />
      <meta name="citation_reference" content="citation_title=Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cellspecificity and promiscuity.; citation_author=HA Masha; citation_author=T Dvora; citation_author=G Evgeny; citation_author=P Israel; citation_author=B Chaim; citation_journal_title=Proc Nati Acad Sci U S A; citation_volume=91; citation_number=28; citation_pages=4872-4876; citation_date=1994; " />
      <meta name="citation_reference" content="citation_title=Epstein-Barr virus transformation.; citation_author=SH Speck; citation_author=JL Strominger; citation_journal_title=Prog Nucleic Acid Res Mol Biol; citation_volume=34; citation_number=29; citation_pages=189-207; citation_date=1987; " />
      <meta name="citation_reference" content="citation_title=Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association.; citation_author=J Hammer; citation_author=F Gallazzi; citation_author=E Bono; citation_author=RW Karr; citation_author=J Guenot; citation_journal_title=J Exp Med; citation_volume=181; citation_number=30; citation_pages=1847-1855; citation_date=1995; " />
      <meta name="citation_reference" content="citation_title=Structural requirements for the biological activity of thymopentin analogs.; citation_author=AH George; citation_author=A Tapan; citation_author=K Daniel; citation_author=G Goldstein; citation_journal_title=Archs Biochem Biophysics; citation_volume=242; citation_number=31; citation_pages=248-255; citation_date=1985; " />
      <meta name="citation_reference" content="citation_title=Peptide length variants p2Ca and QL9 present distinct conformations to Ld-specific T cells.; citation_author=MCH Tara; citation_author=MM Shiloh; citation_author=BM Nancy; citation_author=MC Janet; citation_journal_title=J Immunol; citation_volume=167; citation_number=32; citation_pages=4207-4214; citation_date=2001; " />
      <meta name="citation_reference" content="citation_title=Crystal structures of HLA-A*0201 complexed with either the amino- or carboxyl-terminal group substituted by a methyl group.; citation_author=M Bouvier; citation_author=HC Guo; citation_author=KJ Smith; citation_author=DC Wiley; citation_journal_title=Proteins; citation_volume=33; citation_number=33; citation_pages=97-106; citation_date=1998; " />
      <meta name="citation_reference" content="citation_title=Ovalbumin (323–339) peptide binds to the major histocompatibility complex class II I-Ad protein using two functionally distinct registers.; citation_author=BJ McFarland; citation_author=AJ Sant; citation_author=TP Lybrand; citation_author=C Beesona; citation_journal_title=Biochemistry; citation_volume=38; citation_number=34; citation_pages=16663-16670; citation_date=1999; " />
      <meta name="citation_reference" content="citation_title=DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323–339 epitope.; citation_author=JM Robertson; citation_author=PE Jensen; citation_author=BD Evavold; citation_journal_title=J Immunol; citation_volume=164; citation_number=35; citation_pages=4706-4712; citation_date=2000; " />
      <meta name="citation_reference" content="citation_title=Solid Phase peptide synthesis. The synthesis of a tetrapeptide.; citation_author=RB Merrifield; citation_journal_title=J Am Chem Soc; citation_volume=85; citation_number=36; citation_pages=2149-2154; citation_date=1963; " />
      <meta name="citation_reference" content="citation_title=The structure and mechanism of human calcitonin fibrils.; citation_author=T Arvinte; citation_author=A Cudd; citation_author=AF Drake; citation_journal_title=J Biol Chem; citation_volume=268; citation_number=37; citation_pages=6415-6422; citation_date=1993; " />
      <meta name="citation_reference" content="citation_title=Brooks III: MMTSB tool set: enhanced sampling and multiscale modeling methods for applications in structural biology.; citation_author=M Feig; citation_author=K John; citation_author=L Charles; citation_journal_title=J Mol Graphics Modell; citation_volume=22; citation_number=38; citation_pages=377-395; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=Electrostatic effects in proteins: comparison of dielectric and charge models.; citation_author=EL Mehler; citation_author=T Solmajer; citation_journal_title=Protein Eng; citation_volume=4; citation_number=39; citation_pages=903-910; citation_date=1991; " />
      <meta name="citation_reference" content="citation_title=A physical reference state unifies the structure-derived potential of mean force for protein folding and binding.; citation_author=S Liu; citation_author=C Zhang; citation_author=H Zhou; citation_author=Y Zhou; citation_journal_title=Proteins; citation_volume=56; citation_number=40; citation_pages=93-101; citation_date=2004; " />
      <meta name="citation_reference" content="citation_title=The PyMOL molecular graphics system.; citation_author=WL DeLano; citation_number=41; citation_date=2002; citation_publisher=DeLano Scientific; " />
      <meta name="citation_reference" content="citation_title=LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions.; citation_author=AC Wallace; citation_author=RA Laskowski; citation_author=JM Thornton; citation_journal_title=Prot Eng; citation_volume=8; citation_number=42; citation_pages=127-134; citation_date=1995; " />

  <link rel="canonical" href="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001348" />

    <meta name="twitter:card" content="summary"/>
    <meta name="twitter:site" content="@plosone"/>
    <meta name="twitter:title" content="Molecular Analysis of Thymopentin Binding to HLA-DR Molecules"/>
    <meta name="twitter:description" content="Thymopentin (TP5) triggers an immune response by contacting with T cells; however the molecular basis of how TP5 achieves this process remains incompletely understood. According to the main idea of immunomodulation, we suppose that it would be necessary for TP5 to form complex with human class II major histocompatibility complex DR molecules (HLA-DR) before TP5 interacts with T cells. The uptake of TP5 by EBV-transformed B cells expressing HLA-DR molecules and the histogram of fluorescence intensities were observed by using fluorescent- labeled TP5, testifying the direct binding of TP5 to HLA-DR. The binding specificity was confirmed by the inhibition with unlabeled TP5, suggesting the recognition of TP5 by HLA-DR. To confirm the interaction between TP5 and HLA-DR, the complex formation was predicted by using various modeling strategies including six groups of trials with different parameters, alanine substitutions of TP5, and the mutants of HLA-DR. The results demonstrated that TP5 and its alanine substitutions assumed distinct conformations when they bound to HLA-DR. The observation further showed that there was flexibility in how the peptide bound within the binding cleft. Also, the molecular analysis supplemented a newly important discovery to the effect of Val anchor on TP5 binding HLA-DR, and revealed the important effects of Glu11 and Asn62 on the recognition of TP5. These results demonstrated the capability of TP5 to associate with HLA-DR in living antigen presenting cells (APC), thereby providing a new and promising strategy to understand the immunomodulation mechanism induced by TP5 and to design potential immunoregulatory polypeptides."/>
      <meta name="twitter:image" content="http://dx.plos.org/10.1371/journal.pone.0001348.g007"/>

  <meta property="og:title" content="Molecular Analysis of Thymopentin Binding to HLA-DR Molecules" />
  <meta property="og:type" content="article" />
  <meta property="og:url" content="http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001348" />

 <!--end articleInfoX-->

  <link rel="pingback" href="http://www.plosone.org/pingback" />


  <link rel="shortcut icon" href="/images/favicon.ico" type="image/x-icon"/>
  <link rel="home" title="home" href="/"/>
  <link rel="alternate" type="application/rss+xml"
        title="PLOS ONE: New Articles"
        href="http://www.plosone.org/article/feed"/>
</head>
<body>

  <div id="page-wrap">
    <div id="topbanner" class="cf">

<!-- Div for the ad at the top of journal home page-->
<div class="center">
  <div class="title">Advertisement</div>
  <iframe id='a3ac9da4' name='a3ac9da4'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=345&amp;cb=194'
    frameborder='0' scrolling='no' width='730' height='90'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a3ac9da4&amp;cb=9445'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=345&amp;cb=3807&amp;n=a3ac9da4'
      border='0' alt=''/>
    </a>
  </iframe>
</div>    </div>

    <div id="pagehdr-wrap">
      <div id="pagehdr">
        <div id="user" class="nav">
          <ul>
            <li><a href="http://www.plos.org">plos.org</a></li>
            <li><a href="https://register.plos.org/ambra-registration/register.action">create account</a></li>
            <li class="btn-style"><a
              href="/user/secure/secureRedirect.action?goTo=%2Farticle%2FfetchArticle.action%3FarticleURI%3Dinfo%253Adoi%252F10.1371%252Fjournal.pone.0001348">sign in</a>
            </li>
          </ul>
        </div>
        <div class="logo">
          <a href="/"><img src="/images/logo.png" alt="PLOS ONE"></a>
        </div>

<div id="nav-main" class="nav">
  <ul>
        <li id="mn-01"><a href="/taxonomy" class="areas-link">Subject Areas</a></li>
    <li id="mn-02"><a href="javascript:void(0);">For Authors</a>
      <div class="submenu" style="width: 540px; margin-left: -300px;">
        <div class="block">
          <div class="submit-script">
            <h3>Submit your Manuscript</h3>
            <ul>
              <li>Fair, rigorous peer review</li>
              <li>Broad scope and wide reach</li>
            </ul>
            <a href="/static/submissionInstructions" class="btn">get started</a>
          </div>
        </div>
        <div class="menu">
          <ul>
            <li><a href="/static/publish">Why Publish with PLOS ONE</a></li>
            <li><a href="/static/publication">Publication Criteria</a></li>
            <li><a href="/static/editorial">Editorial Policies</a></li>
            <li><a href="/static/guidelines">Preparing A Manuscript</a></li>
            <li><a href="/static/figureGuidelines">Figure and Table Guidelines</a></li>
          <li><a href="/static/supportingInformation">Supporting Information Guidelines</a></li>
            <li><a href="/static/submissionInstructions">Submitting a Manuscript</a></li>
          </ul>
        </div>
      </div>
    </li>

    <li id="mn-03"><a href="javascript:void(0);">About Us</a>
      <div class="submenu" style="width:248px; margin-left:-30px;">
        <div class="menu">
          <ul>
            <li><a href="/static/information">Journal Information</a></li>
            <li><a href="/static/edboard">Editorial Board</a></li>
            <li><a href="/static/reviewerGuidelines">Reviewer Guidelines</a></li>
            <li><a href="/static/almInfo">Article-Level Metrics</a></li>
            <li><a href="/static/license">Open-Access License</a></li>
            <li><a href="/static/downloads">Media Downloads</a></li>
            <li><a href="/static/commentGuidelines">Guidelines for Comments</a></li>
            <li><a href="/static/corrections">Corrections</a></li>
            <li><a href="/static/help">Help Using this Site</a></li>
            <li><a href="/static/contact">Contact Us</a></li>
          </ul>
        </div>
      </div>
    </li>
  </ul>
<div id="db">
  <form name="searchForm" action="/search/simple?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0001348" method="get" >
<input type="hidden" name="from" value="globalSimpleSearch" id="from"/><input type="hidden" name="filterJournals" value="PLoSONE" id="filterJournals"/>    <fieldset>
      <legend>Search</legend>
      <label for="search">Search</label>
      <div class="wrap">
        <input id="search" type="text" name="query" placeholder="Search">
        <input type="image" alt="SEARCH" src="/images/icon.search.gif">
      </div>
    </fieldset>
  </form>
    <a id="advSearch" href="/search/advanced?noSearchFlag=true&amp;query=&amp;articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0001348&filterJournals=PLoSONE">advanced search</a>
</div></div>

      </div>
      <!-- pagehdr-->
    </div>
    <!-- pagehdr-wrap -->

  <!--body and html tags gets closed in global_footer.ftl-->
<script type="text/javascript" src="/javascript/mathjax/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>

<div id="pagebdy-wrap">
  <div id="pagebdy">

    <div id="article-block" class="cf">

<div class="article-meta cf">
  <ul id="almSignPost" style="display: none;"></ul>
  <div class="article-type">
    <span class="type oa">Open Access</span>
      <span class="type pr">Peer-Reviewed</span>
  </div>
</div>

<div class="header" id="hdr-article">

<div class="article-kicker">
      <span id="article-type-heading">
        Research Article
      </span>
</div>  <h1 property="dc:title" datatype="" rel="dc:type" href="http://purl.org/dc/dcmitype/Text">
    Molecular Analysis of Thymopentin Binding to HLA-DR Molecules
  </h1>

  <ul class="authors">
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Zuojia Liu, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Xiliang Zheng, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              

                <p>Affiliation:
                  State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Jin Wang
              <span class="corresponding">mail</span>, 
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              <p><span class="email">*</span>To whom correspondence should be addressed. E-mail: <a href="mailto:jin.wang.1@stonybrook.edu">jin.wang.1@stonybrook.edu</a> (JW); <a href="mailto:ekwang@ciac.jl.cn">ekwang@ciac.jl.cn</a> (EW)</p>

                <p>Affiliations:
                  State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China, 
                  Department of Chemistry and Physics, State University of New York, Stony Brook, New York, United States of America
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
      <li>


        <span rel="dc:creator" class="author">
          <span class="person" property="foaf:name" typeof="foaf:Person">
            Erkang Wang
              <span class="corresponding">mail</span>
          </span>
        </span>

          <div class="author_meta">
            <div class="author_inner">


              
              <p><span class="email">*</span>To whom correspondence should be addressed. E-mail: <a href="mailto:jin.wang.1@stonybrook.edu">jin.wang.1@stonybrook.edu</a> (JW); <a href="mailto:ekwang@ciac.jl.cn">ekwang@ciac.jl.cn</a> (EW)</p>

                <p>Affiliation:
                  State Key Laboratory of Electroanalytical Chemistry, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, Jilin, China
                </p>


              <span class="close">X</span>

            </div>
          </div>
      </li>
  </ul>
  <ul class="date-doi-line">
    <li>Published: December 26, 2007</li>
    <li>DOI: 10.1371/journal.pone.0001348</li>
  </ul>


</div><!--end header-->
<div class="main cf" id="pjax-container">
  

<div class="nav items-5" id="nav-article">
  <ul>
  <li>
        <span class="active" name="article">Article</span>
  </li>
  <li>
      <a href="/article/authors/info%3Adoi%2F10.1371%2Fjournal.pone.0001348" name="authors">About the Authors</a>
  </li>
  <li>
      <a href="/article/metrics/info%3Adoi%2F10.1371%2Fjournal.pone.0001348" name="metrics">Metrics</a>
  </li>
  <li>
      <a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0001348" name="comments">Comments</a>
  </li>
  <li>
      <a href="/article/related/info%3Adoi%2F10.1371%2Fjournal.pone.0001348" name="related">Related Content</a>
  </li>
  </ul>
</div>

<script type="text/javascript">
  var selected_tab = "article";
</script>
  <div id="figure-thmbs" class="carousel cf">
    <div class="wrapper">
      <div class="slider">
              <div class="item">
                <a href="#pone-0001348-g001" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.g001" title="Figure 1">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g001&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001348-g002" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.g002" title="Figure 2">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g002&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001348-g003" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.g003" title="Figure 3">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g003&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001348-g004" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.g004" title="Figure 4">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g004&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001348-g005" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.g005" title="Figure 5">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g005&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001348-t001" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.t001" title="Table 1">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.t001&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001348-g006" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.g006" title="Figure 6">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g006&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001348-t002" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.t002" title="Table 2">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.t002&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001348-t003" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.t003" title="Table 3">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.t003&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
              <div class="item">
                <a href="#pone-0001348-g007" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.g007" title="Figure 7">
                  <span class="thmb-wrap">
                    <img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g007&representation=PNG_I" alt="">
                  </span>
                </a>
              </div>
      </div>
    </div>
  </div>

  <div class="nav-col">
    <div class="nav" id="nav-article-page">
      <ul>
        <li class="nav-col-comments"><a href="/article/comments/info%3Adoi%2F10.1371%2Fjournal.pone.0001348">Reader Comments (1)</a></li>
          <li id="nav-figures"><a data-doi="info:doi/10.1371/journal.pone.0001348" >Figures</a></li>
      </ul>
    </div>
  </div>

  <div class="article">







<div class="abstract"><a id="abstract0" name="abstract0" toc="abstract0" title="Abstract"></a><h2>Abstract</h2><a id="article1.front1.article-meta1.abstract1.p1" name="article1.front1.article-meta1.abstract1.p1"></a><p>Thymopentin (TP5) triggers an immune response by contacting with T cells; however the molecular basis of how TP5 achieves this process remains incompletely understood. According to the main idea of immunomodulation, we suppose that it would be necessary for TP5 to form complex with human class II major histocompatibility complex DR molecules (HLA-DR) before TP5 interacts with T cells. The uptake of TP5 by EBV-transformed B cells expressing HLA-DR molecules and the histogram of fluorescence intensities were observed by using fluorescent- labeled TP5, testifying the direct binding of TP5 to HLA-DR. The binding specificity was confirmed by the inhibition with unlabeled TP5, suggesting the recognition of TP5 by HLA-DR. To confirm the interaction between TP5 and HLA-DR, the complex formation was predicted by using various modeling strategies including six groups of trials with different parameters, alanine substitutions of TP5, and the mutants of HLA-DR. The results demonstrated that TP5 and its alanine substitutions assumed distinct conformations when they bound to HLA-DR. The observation further showed that there was flexibility in how the peptide bound within the binding cleft. Also, the molecular analysis supplemented a newly important discovery to the effect of Val anchor on TP5 binding HLA-DR, and revealed the important effects of Glu11 and Asn62 on the recognition of TP5. These results demonstrated the capability of TP5 to associate with HLA-DR in living antigen presenting cells (APC), thereby providing a new and promising strategy to understand the immunomodulation mechanism induced by TP5 and to design potential immunoregulatory polypeptides.</p>
</div>


<div class="articleinfo"><p><strong>Citation: </strong>Liu Z, Zheng X, Wang J, Wang E (2007) Molecular Analysis of Thymopentin Binding to HLA-DR Molecules. PLoS ONE 2(12):
          e1348.
            doi:10.1371/journal.pone.0001348</p><p><strong>Academic Editor: </strong>Martin Egli, Vanderbilt University, United States of America</p><p><strong>Received:</strong> May 30, 2007; <strong>Accepted:</strong> November 17, 2007; <strong>Published:</strong> December 26, 2007</p><p><strong>Copyright:</strong> © 2007 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p><p><strong>Funding: </strong>This work was supported by the National Natural Science Foundation of China with the Grant No. 20575063, 90713022, 20735003 and Chinese Academy of Sciences KJCX2.YW.H09. J. W thanks National Science Foundation Career Award and American Chemical Society Petroleum Research Fund for financial supports. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p><p><strong>Competing interests:</strong> The authors have declared that no competing interests exist.</p></div>





<div id="section1" class="section"><a id="s1" name="s1" toc="s1" title="Introduction"></a><h3>Introduction</h3><a id="article1.body1.sec1.p1" name="article1.body1.sec1.p1"></a><p>Thymopentin (TP5) is a synthetic pentapeptide, corresponding to position 32~36 of thymopoietin <a href="#pone.0001348-Solmajer1">[1]</a>. TP5 exhibits a similarly biological activity as thymopoietin responsible for phenotypic differentiation of T cells and the regulation of immune systems <a href="#pone.0001348-Goldstein1">[2]</a>. It had been recognized as an immunomodulator for the treatment of primary immunodeficiencies, such as AIDS <a href="#pone.0001348-Singh1">[3]</a>, rheumatoid arthris (RA) <a href="#pone.0001348-Sundal1">[4]</a> and autoimmune diseases <a href="#pone.0001348-Bodey1">[5]</a> etc. Although the biological role of TP5 has been well elucidated by making contact with T cells, relatively few efforts have been made to clarify the refined mechanism of its action. For the standard paradigm of T-cell mediated immune response, T cell receptors (TCRs) only recognize foreign antigens stably bound to MHC molecules <a href="#pone.0001348-Robert1">[6]</a>–<a href="#pone.0001348-Krebs1">[10]</a>. Recently, it had been shown that human CD 4 T cells expressed functional class II major histocompatibility complex molecules (MHC II) <a href="#pone.0001348-Clare1">[11]</a>. Thus, we deduce that it would be necessary for TP5 to form complex with MHC II molecules before it interacts with T cells.</p>
<a id="article1.body1.sec1.p2" name="article1.body1.sec1.p2"></a><p>MHC II molecules are proteins anchored in the cell membrane of APC, where they present antigenic peptides to CD4 positive T helper cells <a href="#pone.0001348-Lazavecchia1">[12]</a>, <a href="#pone.0001348-Buus1">[13]</a>. Recent advances had provided insights into how MHC interacted with peptides <a href="#pone.0001348-Jensen1">[14]</a>–<a href="#pone.0001348-Cepellini1">[22]</a> and a rationale to predict optimal epitopes of MHC-binding <a href="#pone.0001348-Theodore1">[23]</a>, <a href="#pone.0001348-Kai1">[24]</a>. It is important to note that most of the well-known ligands were derived from naturally MHC-bound peptides and T-restricted epitopes. For synthetic peptides known as clinical drugs, there are few reports on their direct binding MHC in living APC.</p>
<a id="article1.body1.sec1.p3" name="article1.body1.sec1.p3"></a><p>In the present study, we have established combined experimental and computational strategies to verify the hypothesis of the complex formation of MHC II/TP5. Taking advantage of confocal-laser scanning microscopy (CLSM) and flow cytometry (FCM) techniques, we examined the binding of fluorescent-labeled TP5 to HLA-DR in living APC <em>in situ</em> with an apparent dissociation constant (<em>K</em><sub>d</sub>) of 7.2×10<sup>−6</sup> M. Furthermore, the binding specificity was tested by competitive binding assay with unlabeled TP5. The molecular modeling of the interaction between ligands and receptors demonstrated that TP5 and its alanine substitutions adopted distinct conformations when they bound to HLA-DR. The observation further showed that there was flexibility in peptide binding with MHC II binding cleft. More importantly, the molecular analysis supplemented a newly important discovery to the effect of Val anchor on TP5 binding HLA-DR. Also, the molecular analysis revealed the key effects of Glu11 and Asn62 on the recognition of TP5 based on the mutants of HLA-DR. The study provides a better understanding to the mechanism of interaction between TP5 and TCRs and a rational strategy to design TP5 analogs.</p>
</div>

<div id="section2" class="section"><a id="s2" name="s2" toc="s2" title="Results"></a><h3>Results</h3>
<h4>Uptake of FITC-labeled TP5 by EBV-transformed B cells</h4>
<a id="article1.body1.sec2.sec1.p1" name="article1.body1.sec2.sec1.p1"></a><p>To validate the ability of FITC-labeled TP5 to load on EBV-transformed B cells expressing HLA-DR, a qualitative CLSM assay was used to examine the fluorescent signal of EBV-transformed B cells. The surface fluorescence was hardly observed from the cells in the absence of FITC-labeled TP5 at the excitation of 488 nm (<a href="#pone-0001348-g001">Fig. 1A</a>). In sharp contrast to this observation, the strong surface fluorescence was found for the cells in the presence of FITC-labeled TP5 at the same conditions (<a href="#pone-0001348-g001">Fig. 1B</a>). These findings indicated that the green fluorescence could attribute to the loading of FITC-labeled TP5 onto the EBV-transformed B cells.</p>
<div class="figure" id="pone-0001348-g001"><div class="img"><a name="pone-0001348-g001" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g001&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.g001"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g001&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g001/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g001/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g001/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g001/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001348.g001.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g001/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g001/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001348.g001.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 1.  <span>Uptake of FITC-labeled TP5 by EBV-transformed B cells.</span></strong></p><a id="article1.body1.sec2.sec1.fig1.caption1.p1" name="article1.body1.sec2.sec1.fig1.caption1.p1"></a><p>Confocal images were taken in living cells in the absence (A) and presence (B) of FITC-labeled TP5. The scale bar corresponds to 20 µm.</p>
<span>doi:10.1371/journal.pone.0001348.g001</span></div>

<h4>Direct binding of FITC-labeled TP5 to EBV-transformed B cells</h4>
<a id="article1.body1.sec2.sec2.p1" name="article1.body1.sec2.sec2.p1"></a><p>Although the uptake of FITC-labeled TP5 in EBV-transformed B cells was confirmed, the correlation between the binding affinity of FITC-labeled TP5 to EBV-transformed B cells and the fluorescence intensity in cells was not showed clearly. Therefore, a quantitative flow cytometric assay was used to get a better insight into the binding affinity of TP5 to HLA-DR on the surface of EBV-transformed B cells. As shown in <a href="#pone-0001348-g002">Fig. 2</a>, the binding of FITC-labeled TP5 to EBV-transformed B cells was in a dose-dependent manner, and the equilibrium could be achieved at 100 µM of antigen. An apparent <em>K</em><sub>d</sub> of 7.2×10<sup>−6</sup> M was obtained from the double- reciprocal plot of the equilibrium binding data (<a href="#pone-0001348-g003">Fig. 3</a>), implying that TP5 markedly bound to HLA-DR. Simultaneously, a correlation with <em>R<sup>2</sup></em> = 0.9903 and a slope of 0.01311 were obtained. We then compared the specific binding of FITC-labeled TP5 to HLA-DR. In <a href="#pone-0001348-g004">Fig. 4</a>, the histogram of fluorescence intensities indicated that almost the same extent cells (94% vs. 95%, respectively) were stained by FITC-labeled TP5 and mAb-DR FITC above the background, with an approximately 3 orders of magnitude increase in mean fluorescence intensity (MFI). The fluorescent signal showed the strongly direct binding of FITC-labeled TP5 to HLA-DR expressed on the surface of EBV-transformed B cells.</p>
<div class="figure" id="pone-0001348-g002"><div class="img"><a name="pone-0001348-g002" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g002&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.g002"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g002&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g002/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g002/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g002/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g002/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001348.g002.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g002/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g002/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001348.g002.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 2.  <span>Direct binding of FITC-labeled TP5 to EBV-transformed B cells.</span></strong></p><a id="article1.body1.sec2.sec2.fig1.caption1.p1" name="article1.body1.sec2.sec2.fig1.caption1.p1"></a><p>The mean binding data for various concentrations of FITC-labeled TP5 were shown as mean fluorescence intensities of triplicates±SD.</p>
<span>doi:10.1371/journal.pone.0001348.g002</span></div><div class="figure" id="pone-0001348-g003"><div class="img"><a name="pone-0001348-g003" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g003&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.g003"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g003&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g003/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g003/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g003/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g003/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001348.g003.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g003/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g003/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001348.g003.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 3.  <span>Double-reciprocal plot of the equilibrium binding data.</span></strong></p><a id="article1.body1.sec2.sec2.fig2.caption1.p1" name="article1.body1.sec2.sec2.fig2.caption1.p1"></a><p>Representative binding data for various concentrations of antigen were expressed as mean fluorescence intensities of triplicates±SD.</p>
<span>doi:10.1371/journal.pone.0001348.g003</span></div><div class="figure" id="pone-0001348-g004"><div class="img"><a name="pone-0001348-g004" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g004&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.g004"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g004&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g004/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g004/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g004/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g004/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001348.g004.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g004/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g004/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001348.g004.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 4.  <span>The binding of FITC-labeled TP5 onto the surface of EBV-transformed B cells.</span></strong></p><a id="article1.body1.sec2.sec2.fig3.caption1.p1" name="article1.body1.sec2.sec2.fig3.caption1.p1"></a><p>EBV-transformed B cells were incubated with PBS alone (trace a), FITC-labeled TP5 (trace b) and mAb-DR FITC (trace c), and then subjected to flow cytometry. The vertical line was the boundary between bound and unbound cells.</p>
<span>doi:10.1371/journal.pone.0001348.g004</span></div>

<h4>Competitive binding assay</h4>
<a id="article1.body1.sec2.sec3.p1" name="article1.body1.sec2.sec3.p1"></a><p>Next, we examined whether the blocking of HLA-DR on the surface of APC would lead to the inhibition of mAb-DR binding. A distinct change of fluorescence intensity was observed when unlabeled TP5 was preincubated with EBV-transformed B cells, followed by incubation with mAb-DR FITC. With increasing the concentrations of TP5, the fluorescence intensity was shifted to low level of MFI (<a href="#pone-0001348-g005">Fig. 5A</a>). The change of MFI was dependent on the concentrations of TP5 used in the competitive binding assay (<a href="#pone-0001348-g005">Fig. 5B</a>). The reduction of MFI indicated that TP5 bound to HLA-DR and inhibited the binding of mAb-DR to HLA-DR. The competitive binding assay implied that the fluorescence intensity was correlated with the amount of HLA-DR on the surface of APC. The observation further indicated that TP5 restrained the binding of mAb-DR to HLA-DR molecules.</p>
<div class="figure" id="pone-0001348-g005"><div class="img"><a name="pone-0001348-g005" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g005&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.g005"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g005&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g005/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g005/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g005/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g005/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001348.g005.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g005/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g005/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001348.g005.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 5.  <span>Inhibition of the binding of mAb-DR FITC by unlabeled TP5.</span></strong></p><a id="article1.body1.sec2.sec3.fig1.caption1.p1" name="article1.body1.sec2.sec3.fig1.caption1.p1"></a><p>Results were shown by the decrease of MFI (A) and the percent inhibition of MFI (B). The data points shown were the mean values of triplicates±SD.</p>
<span>doi:10.1371/journal.pone.0001348.g005</span></div>

<h4>Molecular modeling of the interaction between TP5 and HLA-DR</h4>
<a id="article1.body1.sec2.sec4.p1" name="article1.body1.sec2.sec4.p1"></a><p>The first five dockings were terminated based on the endpoint of the number of energy evaluations listed in <a href="#pone-0001348-t001">Table 1</a>. As a result, the maximum number of generations was less than 27000 in these runs. Whereas, the sixth docking was terminated based on the endpoint of the maximum number of generations (27000), and the number of energy evaluations was 100 million. From the current data, it could be clearly seen that the number of energy evaluations had an influence on the docking energy generated from six trials. We found that the last trial converged to a stably native binding mode. We also found the binding modes with lowest energy generated from other 5 trials shared some common features with the native binding mode in the last trial. This illustrated that the common features shared by different trials might be crucial for the binding of TP5 to HLA-DR. This means that few stable binding conformations could be found below 100 million energy evaluation.</p>
<div class="figure" id="pone-0001348-t001"><div class="img"><a name="pone-0001348-t001" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.t001&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.t001"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.t001&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.t001/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.t001/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.t001/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.t001/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001348.t001.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.t001/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.t001/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001348.t001.TIF"></span>)
                </a></li></ul></div><p><strong>Table 1.  <span>Docking energies of six groups of trials under different energy evaluations.</span></strong></p><span>doi:10.1371/journal.pone.0001348.t001</span></div><a id="article1.body1.sec2.sec4.p2" name="article1.body1.sec2.sec4.p2"></a><p>More importantly, we found that Gln9 and Lys250, locating in the brim of the binding site, were ineffective to direct peptides to bind into the binding cleft. On the contrary, the interactions between peptide and Glu11 and Asn62 played a key role in orientation, suggesting that both the residues were obligatory during the binding of TP5 into the binding cleft.</p>
<a id="article1.body1.sec2.sec4.p3" name="article1.body1.sec2.sec4.p3"></a><p>On the basis of Autodock3.0.5 method, a certain number of energy evaluations may converge to a correct energy minimum. That implies more members of the populations will be converged to the lowest energy conformation <a href="#pone.0001348-Morris1">[25]</a>. Thus, if the energy evaluation is further increased, the system will be remained at the same conformation. According to the rule, the maximum number of energy evaluations was set to 100 million for the following calculations. Confirming the complex formation between TP5 and HLA-DR, we assessed the ability of HLA-DR to functionally recognize alanine substitutions of TP5 under the same parameters. The best complexes with the lowest binding energy and the same direction between peptides and the groove were used as the inputs for further minimization. In <a href="#pone-0001348-t002">Table 2</a>, the binding energy of TP5 binding to HLA-DR was the least value among six binding energies. This result means that the most stable complex of HLA-DR/TP5 was formed (<a href="#pone-0001348-g006">Fig. 6A</a>). Remarkably, the substitution of Arg at position 1 considerably reduced the binding affinity. However, as shown in <a href="#pone-0001348-g006">Fig. 6B</a>, the alanine substitution of Arg stretched into the cleft deeply and bound to the same binding site with Glu11 and Asn62, which accounted for its obligatory nature for Arg at position 1 for actual interacting with the receptor. In contrast to this observation, the alanine substitution of Lys at position 2 reduced the binding affinity to the minimum extent; the substitution failed to stretch into the same binding site containing Glu11 and Asn62 instead of projecting out the binding groove (<a href="#pone-0001348-g006">Fig. 6C</a>). In particular, the interactions of Arg and Lys with the binding sites ensured the occurrence of binding and the direction of the N-terminal of the peptide. Whereas, the alanine substitution of Val at position 4 reduced the binding affinity to the maximum extent and bound HLA-DR in a distinct manner from TP5, projecting out the cleft (<a href="#pone-0001348-g006">Fig. 6E</a>). The substitution of Asp and Tyr at positions 3 and 5 resulted in a moderate decrease of binding affinity and variant binding sites without Glu11. Interestingly, both the substitutions bound into the binding cleft (<a href="#pone-0001348-g006">Fig. 6D, F</a>). Examination of the docking results revealed that TP5 was predicted to be optimal for binding into the cleft within the MHC molecules.</p>
<div class="figure" id="pone-0001348-g006"><div class="img"><a name="pone-0001348-g006" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g006&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.g006"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g006&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g006/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g006/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g006/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g006/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001348.g006.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g006/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g006/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001348.g006.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 6.  <span>The predicted binding of TP5 and its alanine substitutions to HLA-DR.</span></strong></p><a id="article1.body1.sec2.sec4.fig1.caption1.p1" name="article1.body1.sec2.sec4.fig1.caption1.p1"></a><p>The key residues (E11, N62) are in red; the other contacted residues are in orange. Peptide variants correspond to A: RKDVY; B: AKDVY; C: RADVY; D: RKAVY; E: RKDAY; F: RKDVA.</p>
<span>doi:10.1371/journal.pone.0001348.g006</span></div><div class="figure" id="pone-0001348-t002"><div class="img"><a name="pone-0001348-t002" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.t002&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.t002"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.t002&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.t002/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.t002/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.t002/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.t002/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001348.t002.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.t002/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.t002/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001348.t002.TIF"></span>)
                </a></li></ul></div><p><strong>Table 2.  <span>The effect of alanine substitutions of TP5 on binding HLA-DR.</span></strong></p><span>doi:10.1371/journal.pone.0001348.t002</span></div><a id="article1.body1.sec2.sec4.p4" name="article1.body1.sec2.sec4.p4"></a><p>As mentioned above, the contacted residues Glu11 and Asn62 played a key role in mediating the binding affinity and orientation (<a href="#pone-0001348-t002">Table 2</a>). In order to verify their effects on the binding between TP5 and HLA-DR, the HLA-DR double mutant, replacing E11 and N62 with alanine (DR11/62), and two single mutants, DRE11A (DR11), and DRN62A (DR62), were used as controls. From <a href="#pone-0001348-t003">Table 3</a>, when TP5 bound to the mutant DR11, the binding energy had a slight change; however, Ala11 completely lost its role as a binding site. Whereas, when TP5 bound to the mutant DR62, the binding energy had a distinct change; Ala62 remained to exert a positive role as a binding site, suggesting that Asn anchor mainly contributed to the binding energy. When the mutant DR11/62 was used, the binding energy increased markedly which was basically equal to the sum of both the values above predicted, demonstrating that Glu11 and Asn62 played their respective role in the double mutant. These data suggested that the complex of HLA-DR/TP5 was the most stable, and further indicated that the molecular modeling was feasible for supporting the assumption of TP5 binding to HLA-DR.</p>
<div class="figure" id="pone-0001348-t003"><div class="img"><a name="pone-0001348-t003" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.t003&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.t003"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.t003&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.t003/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.t003/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.t003/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.t003/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001348.t003.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.t003/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.t003/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001348.t003.TIF"></span>)
                </a></li></ul></div><p><strong>Table 3.  <span>The effect of the mutants of HLA-DR on the recognition of TP5.</span></strong></p><span>doi:10.1371/journal.pone.0001348.t003</span></div>
</div>

<div id="section3" class="section"><a id="s3" name="s3" toc="s3" title="Discussion"></a><h3>Discussion</h3><a id="article1.body1.sec3.p1" name="article1.body1.sec3.p1"></a><p>The role of TP5 in clinical treatment in immune system was well established, however, the refined mechanism of its action is not known in details. According to the main idea of immunomodulation, we suppose that it were obligatory for TP5 to form complex with MHC II before TP5 interacts with TCRs. For class II MHC molecules, they bound peptides with various length <a href="#pone.0001348-Singh1">[3]</a>. More importantly, a tentative DR motif that governs the fine-specificity of antigen presentation had been well known recently <a href="#pone.0001348-Rammensee1">[26]</a>. For TP5, it contains Val and Tyr residues which belong to basic anchor motifs, providing multiple interaction sites. Especially, TP5 possesses a linear peptide whose structural flexibility may allow it to associate with different receptors through conformational changes. According to the rule of set of allowed anchor residues (SAAR) <a href="#pone.0001348-Rammensee1">[26]</a>, TP5 is theoretically expected to bind HLA-DR.</p>
<a id="article1.body1.sec3.p2" name="article1.body1.sec3.p2"></a><p>We report the first direct observation of MHC II/TP5 complex formed in living APC <em>in situ</em>. On the basis of the double-reciprocal plot of the dose-dependent fluorescence intensities (<a href="#pone-0001348-g003">Fig. 3</a>), the <em>K</em><sub>d</sub> (7.2×10<sup>−6 </sup>M) is close to the reported <em>K</em><sub>d </sub>value <a href="#pone.0001348-Grey1">[27]</a>. Furthermore, with increasing the concentrations of TP5 in the range of 10<sup>−5 </sup>M to 10<sup>−2 </sup>M, the fluorescence intensity decreased (<a href="#pone-0001348-g005">Fig. 5A</a>), reaching 36% inhibition at the concentration of 10<sup>−2 </sup>M as shown in <a href="#pone-0001348-g005">Fig. 5B</a>. The inhibition was similar to the observation of human EBV-transformed B cells inhibited by anti-HLA-DR antibody reaching 44–52% <a href="#pone.0001348-Masha2">[28]</a>. The comparability in the level of inhibition could be due to the higher levels of MHC II on the surface of EBV-transformed B cells <a href="#pone.0001348-Speck1">[29]</a> and the occupied binding sites of MHC II <a href="#pone.0001348-Goldstein1">[2]</a>. The main findings indicated that MHC II/TP5 complex was formed by the binding of TP5 to HLA-DR in living cells. The affinity measured using living EBV-transformed B cells are more applicable for functional recognition of MHC II/peptide by T cells.</p>
<a id="article1.body1.sec3.p3" name="article1.body1.sec3.p3"></a><p>As far as MHC-binding motifs are concerned, anchors can be divided into two different types: type 1 anchors that contribute to the binding energy of the peptide, and type 2 anchors that contribute to the peptide conformation <a href="#pone.0001348-Hammer1">[30]</a>. Here, we performed molecular modeling evaluations to analyze the interaction between the anchors in the frame of TP5 and the binding sites within the groove of HLA-DR. The alanine substitutions of TP5 were tested for HLA-DR binding affinity. From the binding energies presented in <a href="#pone-0001348-t002">Table 2</a>, it can be observed that the substitution at positions 1 and 4 had a significant effect on the binding affinity; the substitution at other positions resulted in only partial loss of binding affinity. It implied that the substitution of TP5 at positions 1 and 4 formed instable complexes with HLA-DR. Further, the anchor at positions 1 and 4 seemed to be obligatory as type 1 anchors due to decreasing the binding affinity by Ala substitution. It was also noteworthy that the substitution at positions 2 and 4 neither bound to the same binding sites containing Glu11 and Asn62 nor stretched into the binding groove (<a href="#pone-0001348-g006">Fig. 6C, E</a>). This observation suggested that anchors at positions 2 and 4 mainly exerted an effect on peptide conformation, and further implied that the conformation of DR-bound peptide should be very similar. With regard to positions 3 and 5, the substitution by Ala resulted in a moderate binding affinity decrease and variant binding sites containing Asn62 without Glu11, suggesting that peptides with several anchors in frame were more likely to bind to a particular binding site than those lacking partial anchors in frame. The variation of binding affinity showed that anchors at positions 1, 3 and 5 in the frame of TP5 actually interacted with the receptor HLA-DR; however, anchor at position 2 primarily involved in steric constraints. As for the Val at position 4, although the amino acid served as type 2 anchors identified in previous study <a href="#pone.0001348-George1">[31]</a>, the contribution as type 1 anchors is more in the present study. This observation exhibits an obligatory role for Val anchor which is essential for HLA-DR/peptide interaction. The functional analysis of TP5 is basically consistent with previous study on the role of each amino acid in frame <a href="#pone.0001348-George1">[31]</a> other than supplementing an important discovery to the effect of Val on TP5 binding receptor as type 1 anchors.</p>
<a id="article1.body1.sec3.p4" name="article1.body1.sec3.p4"></a><p>The alanine-substituted peptide variants bound less well to HLA-DR than TP5 did, suggesting that Ala in the substitutions exerted its effect indirectly by inducing a conformational change. Especially, substitution of the N- and C-terminal residues with Ala had revealed some unpredictably conformational changes both in central peptide residues and in the MHC other than affecting the stability of the complexes <a href="#pone.0001348-Tara1">[32]</a>, <a href="#pone.0001348-Bouvier1">[33]</a>. Thus, the substitution of anchors can alter overall peptide conformation. Simultaneously, as shown in <a href="#pone-0001348-g006">Fig. 6</a>, the binding space of TP5 and its alanine substitutions in binding grooves was larger than that of the longer peptides. Thus, the binding groove likely permits flexibility in peptides binding, which had been demonstrated before <a href="#pone.0001348-McFarland1">[34]</a>, <a href="#pone.0001348-Robertson1">[35]</a>. The results provide significant evidences that peptide variants by a single Ala-substituted assume distinct conformations when they bound to HLA-DR. In other words, the results show that there is flexibility in peptide binding within the MHC II binding cleft.</p>
<a id="article1.body1.sec3.p5" name="article1.body1.sec3.p5"></a><p>In an attempt to gain insight into the interaction pattern, we studied the influence of site-directed mutants of HLA-DR on the peptide binding. The results demonstrated that Glu11 exerted its role of binding site through forming H-bond by the interaction of its side chain with the Lys anchor in the frame of TP5 (<a href="#pone-0001348-g007">Fig. 7A, C</a>). Conversely, Ala11 completely lost the ability to interact with TP5 due to the lack of negative residue in its side chain (<a href="#pone-0001348-g007">Fig. 7B, D</a>), which showed that Glu11 acted as a key effect on the binding between TP5 and HLA-DR. DR62 resulted in significantly lower binding affinity to level comparable to the binding by original DR (<a href="#pone-0001348-t003">Table 3</a>). It can be seen that Asn62 interacted with the Arg and Asp anchors in the frame of TP5 by its side chain (<a href="#pone-0001348-g007">Fig. 7A, B</a>). However, Ala62 completely lost the interaction with TP5 by its side chain oxygen which was replaced by the main-chain oxygen of Ala62 (<a href="#pone-0001348-g007">Fig. 7C, D</a>), suggesting that the interaction by the main chain weakened the binding affinity. The results examining the recognition of the mutations of HLA-DR provided a sufficient basis for the prediction of Glu11 and Asn62 within the groove exerting respective effect on the binding pattern.</p>
<div class="figure" id="pone-0001348-g007"><div class="img"><a name="pone-0001348-g007" title="Click for larger image " href="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g007&amp;representation=PNG_M" data-doi="info:doi/10.1371/journal.pone.0001348" data-uri="info:doi/10.1371/journal.pone.0001348.g007"><img src="/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0001348.g007&amp;representation=PNG_I" alt="thumbnail" class="thumbnail"></a></div><div class="figure-inline-download">
            Download:
            <ul><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g007/powerpoint">
                    PPT
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g007/powerpoint">
                  PowerPoint slide
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g007/largerimage">
                    PNG
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g007/largerimage">
                  larger image
                  (<span id="info:doi/10.1371/journal.pone.0001348.g007.PNG_L"></span>)
                </a></li><li><div class="icon"><a href="/article/info:doi/10.1371/journal.pone.0001348.g007/originalimage">
                    TIFF
                  </a></div><a href="/article/info:doi/10.1371/journal.pone.0001348.g007/originalimage">
                  original image
                  (<span id="info:doi/10.1371/journal.pone.0001348.g007.TIF"></span>)
                </a></li></ul></div><p><strong>Figure 7.  <span>The 2D schemes of the predicted binding of TP5 to HLA-DR and its mutants.</span></strong></p><a id="article1.body1.sec3.fig1.caption1.p1" name="article1.body1.sec3.fig1.caption1.p1"></a><p>The schemes of TP5 binding HLA-DR (A), DR11 (B), DR62 (C), and DR11/62 (D) were resulted from the Ligplot program <a href="#pone.0001348-Wallace1">[42]</a>.</p>
<span>doi:10.1371/journal.pone.0001348.g007</span></div><a id="article1.body1.sec3.p6" name="article1.body1.sec3.p6"></a><p>The collectively experimental and computational studies supported the hypothesis that TP5 bound to HLA-DR with stable conformation, and clarified the distribution of residue-residue between the peptide and the receptor. This report focused on the exploration of the binding affinity of TP5 to MHC II, which was essential to understand the mechanism of TP5 triggering immune response <em>in vivo</em>. More significantly, identification of the interaction between TP5 and HLA-DR will advance our ability to develop polypeptides for the study of MHC class II-restricted CD4+ T lymphocyte responses.</p>
</div>

<div id="section4" class="section"><a id="s4" name="s4" toc="s4" title="Materials and Methods"></a><h3>Materials and Methods</h3>
<h4>Peptide synthesis and conjugation with FITC</h4>
<a id="article1.body1.sec4.sec1.p1" name="article1.body1.sec4.sec1.p1"></a><p>TP5 was synthesized and purified as described previously <a href="#pone.0001348-Merrifield1">[36]</a>. Conjugation of TP5 with Fluorescein isothiocyanate (FITC) (Sigma, St.Louis, USA) was performed and purified as described previously <a href="#pone.0001348-Arvinte1">[37]</a>. The identity of FITC-labeled TP5 was conducted by laser-induced fluorescence spectral analysis (PTI, London Ontario, Canada).</p>


<h4>Cell culture</h4>
<a id="article1.body1.sec4.sec2.p1" name="article1.body1.sec4.sec2.p1"></a><p>EBV-transformed B cells expressing HLA-DR molecules were maintained in RPMI 1640 containing 2 mM L-glutamine (HyClone Laboratories, UT, USA) supplemented with 10% standard FBS (HyClone Laboratories, UT, USA) at 37°C and in 5% CO<sub>2</sub>. Expression of HLA-DR was verified using mAb-DR L243 labeled with FITC (Pharmingen, San Diego, USA), by incubation for 45 min on ice followed by CLSM and FCM.</p>


<h4>Cellular peptide loading assay</h4>
<a id="article1.body1.sec4.sec3.p1" name="article1.body1.sec4.sec3.p1"></a><p>We harvested 3×10<sup>5</sup> cells, washed twice with phosphate-buffered saline (PBS) buffer (pH 7.4) supplemented with 0.1% BSA and 0.05% NaN<sub>3</sub>. Ten µM FITC- labeled TP5 was added to the treated cells in PBS (pH 7.4) containing 1% BSA (binding buffer), then incubated for 2 h at 37°C. Thereafter, the cells were washed twice and resuspended in 500 µl PBS, followed by CLSM analysis using Leica Microsystems (TCS SP2, Heidelberg, Germany).</p>


<h4>Direct binding of FITC-labeled TP5 to EBV-transformed B cells</h4>
<a id="article1.body1.sec4.sec4.p1" name="article1.body1.sec4.sec4.p1"></a><p>EBV-transformed B cells (3×10<sup>5</sup> per sample) were incubated with various concentrations of FITC-labeled TP5 in binding buffer for 2 h at 37°C. Thereafter, the cells were washed twice and resuspended in 500 µl PBS, followed by flow cytometric analysis using a FACSCan analyzer (Becton Dickinson Immunochemical Systems, Mountain View, USA). A total of ten thousand events were acquired for each sample. The MFI was used to evaluate the binding ability of FITC-labeled TP5 to APC.</p>


<h4>Competitive binding assay</h4>
<a id="article1.body1.sec4.sec5.p1" name="article1.body1.sec4.sec5.p1"></a><p>EBV-transformed B cells (3×10<sup>5</sup> per sample) were preincubated in the presence of varying concentrations of TP5 in binding buffer for 2 h at 37°C. Then, the cells were washed and resuspended in 50 µl binding buffer, followed by incubation with 20 µl mAb-DR L243 labeled with FITC for each sample for 45 min on ice in dark. Thereafter, cells were washed twice and analyzed by FCM. In each analysis, ten thousand cells were examined. Percent inhibition was calculated as [(1–MFI in the presence of TP5/MFI in the absence of TP5)×100%].</p>


<h4>Molecular modeling</h4>
<a id="article1.body1.sec4.sec6.p1" name="article1.body1.sec4.sec6.p1"></a><p>Both the numbers of energy evaluations and generations are very important factors for the time that will be consumed and the accurateness of the results that will be got. The docking calculations will be stopped if anyone of the parameters is reached whichever first comes. In this case, to determine the effect of the number of energy evaluations, six groups of trials were performed with 100 runs (<a href="#pone-0001348-t001">Table 1</a>). Six trials with different energy evaluation parameters were chosen for the purpose of exploring which choice could lead to the final binding mode. The maximum number of generations was set to default (27000) so that the docking calculation will be stopped based on the number of energy evaluations. The maximum number of energy evaluations was set to 100 million; the other parameters were defaults. We applied the populations of 300 individuals to 100 independent runs. In addition, the random docking method was applied to predict the complexes between the receptors and the ligands in the Autodock.</p>
<a id="article1.body1.sec4.sec6.p2" name="article1.body1.sec4.sec6.p2"></a><p>Further, the two-step protocol was applied to confirm the complex formation and to examine the interaction between TP5 and HLA-DR. In the present modeling system, HA peptide/HLA-DR complex (PDB code 1J8H) was used as the reference. The structure of TP5 was achieved based on the crystal nonapeptide by mutating method <a href="#pone.0001348-Feig1">[38]</a>. The ligand TP5 was prepared using AutoDockTools. Here, Amber-based “Kollman” partial atomic charges and solvation parameters were applied to the atoms of the receptor (HLA-DR) using the AutoDockTools software package. Kollman charges were assigned to the atoms of the ligand.</p>
<a id="article1.body1.sec4.sec6.p3" name="article1.body1.sec4.sec6.p3"></a><p>In the first phase, TP5 was docked into the binding site by means of the package Autodock 3.0.5 <a href="#pone.0001348-Mehler1">[39]</a>. A three-dimensional grid was created with 0.375 Å spacing with a 126 Å×126 Å×76 Å grid box by the AutoGrid program for the binding site of the receptor, which was used to evaluate the binding energy between the inhibitor and the protein. Lennard-Jones parameters 12–10 and 12–6 were approximately used to simulate H-bonds and Van der Waals interactions, respectively. The distance- dependent dielectric permittivity of Mehler and Solmajer was used for the calculation of the electrostatic grid maps <a href="#pone.0001348-Liu1">[40]</a>. The Lamarckian genetic algorithm, the pseudo-Solis, and Wets methods were applied for minimization by using defaults <a href="#pone.0001348-Mehler1">[39]</a>. Solis and Wets local searches were applied with a probability of 6%. A crossover rate of 80% was used to generate new docking solutions for subsequent generations, and one solution from each generation was propagated to the next generation. Random starting positions on the entire protein surface, random orientations, and torsions, were used for the ligand. Evaluation of the results was performed by sorting the binding energy predicted by docking conformations. A cluster of analysis based on the root mean square deviation (rmsd) value, referring to the starting position of the ligand, was performed subsequently.</p>
<a id="article1.body1.sec4.sec6.p4" name="article1.body1.sec4.sec6.p4"></a><p>In the second phase, the lowest-energy complex predicted by molecular docking was subjected to 1000 steps of energy minimization by using the perl script of minAmber MMTSB_tool for removing clashes and refining complex docked by using an Amber-based procedure <a href="#pone.0001348-Feig1">[38]</a>. Namely, we performed a vacuum minimization of the given structure over 700 steps of final conjugate gradient minimization with 300 steps of initial steepest descent minimization. As a somewhat realistic but very fast method for representing aqueous solvent, we used a distance dependent dielectric function with an epsilon value of 4. The non-bonded cutoff radius was set to 16 Å. With respect to the above minimized complex, the evaluation of the predicted binding energy was made by using the package Dcomplex <a href="#pone.0001348-DeLano1">[41]</a>, which is the program for predicting the binding affinities of protein-protein and protein-peptide complexes based on the Distance-scaled Finite Ideal-gas Reference (DFIRE) energy function. The determination of the interactions between ligands and receptors was illustrated by using the package Pymol based on the minimized structures <a href="#pone.0001348-Wallace1">[42]</a>.</p>
<a id="article1.body1.sec4.sec6.p5" name="article1.body1.sec4.sec6.p5"></a><p>Next, we studied the dockings for alanine substitutions of TP5 through scanning the alanine on each position for the same receptor (HLA-DR). Moreover, the HLA-DR double mutant DR11/62 and two single mutants DR11, and DR62, were used by molecular modeling method for the same ligand TP5. All preparations and parameters were consistent with the contents above described.</p>

</div>





<div><a id="ack" name="ack" toc="ack" title="Acknowledgments"></a><h3>Acknowledgments</h3>
<a id="article1.back1.ack1.p1" name="article1.back1.ack1.p1"></a><p>The author is especially grateful to Prof. Xiongwen Wu for his presentation of the EBV-transformed B cells.</p>
</div><div class="contributions"><a id="authcontrib" name="authcontrib" toc="authcontrib" title="Author Contributions"></a><h3>Author Contributions</h3><p>Conceived and designed the experiments: JW ZL EW. Performed the experiments: zl xz. Analyzed the data: ZL XZ. Wrote the paper: ZL.</p></div><div><a id="references" name="references" toc="references" title="References"></a><h3>References</h3><ol class="references"><li><span class="label">1.
              </span><a name="pone.0001348-Solmajer1" id="pone.0001348-Solmajer1"></a>Solmajer T (1990) Design of a novel thymopoietin analogue based on conformational analyses. Drugs Des Deliv  6: 213–221.  <ul class="find" data-citedArticleID="1033226"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Design+of+a+novel+thymopoietin+analogue+based+on+conformational+analyses.&amp;auth=&amp;atitle=Design+of+a+novel+thymopoietin+analogue+based+on+conformational+analyses." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Design+of+a+novel+thymopoietin+analogue+based+on+conformational+analyses." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Design+of+a+novel+thymopoietin+analogue+based+on+conformational+analyses.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">2.
              </span><a name="pone.0001348-Goldstein1" id="pone.0001348-Goldstein1"></a>Goldstein G, Scheid MP, Schlesinger DH, Wauwe JV (1979) A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin. Science  204: 1309–1310.  <ul class="find" data-citedArticleID="1033176" data-doi="10.1126/science.451537"><li><a href="http://dx.doi.org/10.1126/science.451537" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=A+synthetic+pentapeptide+with+biological+activity+characteristic+of+the+thymic+hormone+thymopoietin." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22A+synthetic+pentapeptide+with+biological+activity+characteristic+of+the+thymic+hormone+thymopoietin.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">3.
              </span><a name="pone.0001348-Singh1" id="pone.0001348-Singh1"></a>Singh VK, Biswas S, Mathur KB, Haq W, Garg SK, et al.  (1998) Thymopentin and splenopentin as immunomodulators, current status. Immunol Res  17: 345–368.  <ul class="find" data-citedArticleID="1033224" data-doi="10.1007/bf02786456"><li><a href="http://dx.doi.org/10.1007/bf02786456" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Thymopentin+and+splenopentin+as+immunomodulators%2C+current+status." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Thymopentin+and+splenopentin+as+immunomodulators%2C+current+status.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">4.
              </span><a name="pone.0001348-Sundal1" id="pone.0001348-Sundal1"></a>Sundal E, Bertelletti D (1994) Management of viral infections with thymopentin. Arzneimittel-forsch  44: 866–871.  <ul class="find" data-citedArticleID="1033230"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Management+of+viral+infections+with+thymopentin.&amp;auth=&amp;atitle=Management+of+viral+infections+with+thymopentin." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Management+of+viral+infections+with+thymopentin." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Management+of+viral+infections+with+thymopentin.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">5.
              </span><a name="pone.0001348-Bodey1" id="pone.0001348-Bodey1"></a>Bodey B, Bodey BJ, Siegel SE, Kaiser HE (2000) Review of thymic hormones in cancer diagnosis and treatment. Int J Immunopharmacol  22: 261–73.  <ul class="find" data-citedArticleID="1033160" data-doi="10.1016/s0192-0561(99)00084-3"><li><a href="http://dx.doi.org/10.1016/s0192-0561(99)00084-3" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Review+of+thymic+hormones+in+cancer+diagnosis+and+treatment." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Review+of+thymic+hormones+in+cancer+diagnosis+and+treatment.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">6.
              </span><a name="pone.0001348-Robert1" id="pone.0001348-Robert1"></a>Robert B, George S, Kevin H, Rothbard JB (1990) Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces. Int Immunol  2: 443–451.  <ul class="find" data-citedArticleID="1033214" data-doi="10.1093/intimm/2.5.443"><li><a href="http://dx.doi.org/10.1093/intimm/2.5.443" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Degenerate+binding+of+immunogenic+peptides+to+HLA-DR+proteins+on+B+cell+surfaces." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Degenerate+binding+of+immunogenic+peptides+to+HLA-DR+proteins+on+B+cell+surfaces.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">7.
              </span><a name="pone.0001348-Santambrogio1" id="pone.0001348-Santambrogio1"></a>Santambrogio L, Aaron K, Sato FR, Fischer ME, Dorf , et al.  (1999) Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc Natn Acad Sci U S A  96: 15050–15055.  <ul class="find" data-citedArticleID="1033220" data-doi="10.1073/pnas.96.26.15050"><li><a href="http://dx.doi.org/10.1073/pnas.96.26.15050" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Abundant+empty+class+II+MHC+molecules+on+the+surface+of+immature+dendritic+cells." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Abundant+empty+class+II+MHC+molecules+on+the+surface+of+immature+dendritic+cells.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">8.
              </span><a name="pone.0001348-Guillet1" id="pone.0001348-Guillet1"></a>Guillet JG, Lai MZ, Briner TJ, Smith JA, Gefter ML (1987) Interaction of peptide antigens and class II major histocompatibility complex antigens. Nature  324: 260–262.  <ul class="find" data-citedArticleID="1033180" data-doi="10.1038/324260a0"><li><a href="http://dx.doi.org/10.1038/324260a0" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Interaction+of+peptide+antigens+and+class+II+major+histocompatibility+complex+antigens." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Interaction+of+peptide+antigens+and+class+II+major+histocompatibility+complex+antigens.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">9.
              </span><a name="pone.0001348-Haward1" id="pone.0001348-Haward1"></a>Haward W, Davidson PA, Lazavecchia RA, Watts C (1991) Processed antigen binds to newly synthesized MHC class II molecules in antigen-specific B lymphocytes. Cell  67: 105–116.  <ul class="find" data-citedArticleID="1033184" data-doi="10.1016/0092-8674(91)90575-j"><li><a href="http://dx.doi.org/10.1016/0092-8674(91)90575-j" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Processed+antigen+binds+to+newly+synthesized+MHC+class+II+molecules+in+antigen-specific+B+lymphocytes." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Processed+antigen+binds+to+newly+synthesized+MHC+class+II+molecules+in+antigen-specific+B+lymphocytes.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">10.
              </span><a name="pone.0001348-Krebs1" id="pone.0001348-Krebs1"></a>Krebs S, Rognan D (1998) From peptides to peptidomimetics: design of nonpeptide ligands for major histocompatibility proteins. Pharm Acta Helv  73: 173–181.  <ul class="find" data-citedArticleID="1033192" data-doi="10.1016/s0031-6865(98)00021-1"><li><a href="http://dx.doi.org/10.1016/s0031-6865(98)00021-1" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=From+peptides+to+peptidomimetics%3A+design+of+nonpeptide+ligands+for+major+histocompatibility+proteins." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22From+peptides+to+peptidomimetics%3A+design+of+nonpeptide+ligands+for+major+histocompatibility+proteins.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">11.
              </span><a name="pone.0001348-Clare1" id="pone.0001348-Clare1"></a>Clare BA, Wolf E, Hafler DA (2006) MHC Class II expression identifies functionally distinct human regulatory T cells. J Immunol  176: 4622–4631.  <ul class="find" data-citedArticleID="1033168"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=MHC+Class+II+expression+identifies+functionally+distinct+human+regulatory+T+cells.&amp;auth=&amp;atitle=MHC+Class+II+expression+identifies+functionally+distinct+human+regulatory+T+cells." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=MHC+Class+II+expression+identifies+functionally+distinct+human+regulatory+T+cells." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22MHC+Class+II+expression+identifies+functionally+distinct+human+regulatory+T+cells.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">12.
              </span><a name="pone.0001348-Lazavecchia1" id="pone.0001348-Lazavecchia1"></a>Lazavecchia AA, Pamela , Watts RC (1992) Irreversible association of peptide with class II MHC molecules in living cells. Nature  357: 249–251.  <ul class="find" data-citedArticleID="1033194" data-doi="10.1038/357249a0"><li><a href="http://dx.doi.org/10.1038/357249a0" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Irreversible+association+of+peptide+with+class+II+MHC+molecules+in+living+cells." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Irreversible+association+of+peptide+with+class+II+MHC+molecules+in+living+cells.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">13.
              </span><a name="pone.0001348-Buus1" id="pone.0001348-Buus1"></a>Buus S, Sette A, Colon SM, Miles C, Grey HM (1987) The relation between major histocompatibility complex (MHC) restriction and the capacity of to bind immunogenic peptides. Science  235: 1353–1358.  <ul class="find" data-citedArticleID="1033164" data-doi="10.1126/science.2435001"><li><a href="http://dx.doi.org/10.1126/science.2435001" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=The+relation+between+major+histocompatibility+complex+%28MHC%29+restriction+and+the+capacity+of+to+bind+immunogenic+peptides." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22The+relation+between+major+histocompatibility+complex+%28MHC%29+restriction+and+the+capacity+of+to+bind+immunogenic+peptides.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">14.
              </span><a name="pone.0001348-Jensen1" id="pone.0001348-Jensen1"></a>Jensen PE (1991) Enhanced binding of peptide antigen to purified class II major histocompatibility glycoproteins at acidic pH. J Exp Med  174: 111–1120.  <ul class="find" data-citedArticleID="1033186" data-doi="10.1084/jem.174.5.1111"><li><a href="http://dx.doi.org/10.1084/jem.174.5.1111" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Enhanced+binding+of+peptide+antigen+to+purified+class+II+major+histocompatibility+glycoproteins+at+acidic+pH." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Enhanced+binding+of+peptide+antigen+to+purified+class+II+major+histocompatibility+glycoproteins+at+acidic+pH.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">15.
              </span><a name="pone.0001348-Masha1" id="pone.0001348-Masha1"></a>Masha FH, Strominger JL (1998) Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immun  160: 4386–4397.  <ul class="find" data-citedArticleID="1033200" data-doi="10.1177/135245859700300616"><li><a href="http://dx.doi.org/10.1177/135245859700300616" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Promiscuous+binding+of+synthetic+copolymer+1+to+purified+HLA-DR+molecules." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Promiscuous+binding+of+synthetic+copolymer+1+to+purified+HLA-DR+molecules.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">16.
              </span><a name="pone.0001348-Sherman1" id="pone.0001348-Sherman1"></a>Sherman MA, Weber DA, Spotts EA, Moore JC, Jensen PE (1997) Inefficient peptide binding by cell-surface class II MHC molecules. Cell Immuno  182: 1–11.  <ul class="find" data-citedArticleID="1033222" data-doi="10.1006/cimm.1997.1219"><li><a href="http://dx.doi.org/10.1006/cimm.1997.1219" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Inefficient+peptide+binding+by+cell-surface+class+II+MHC+molecules." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Inefficient+peptide+binding+by+cell-surface+class+II+MHC+molecules.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">17.
              </span><a name="pone.0001348-Babbit1" id="pone.0001348-Babbit1"></a>Babbit BP, Allen PM, Matsueda G, Haber E, Unanue ER (1985) Binding of immunogenic peptides to Ia histocompatibility molecules. Nature  317: 359–361.  <ul class="find" data-citedArticleID="1033158" data-doi="10.1038/317359a0"><li><a href="http://dx.doi.org/10.1038/317359a0" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Binding+of+immunogenic+peptides+to+Ia+histocompatibility+molecules." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Binding+of+immunogenic+peptides+to+Ia+histocompatibility+molecules.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">18.
              </span><a name="pone.0001348-Luescher1" id="pone.0001348-Luescher1"></a>Luescher IF, Allen PM, Unanue ER (1988) Binding of photoreactive lysozyme peptides to murine histocompatibility class II molecules. Proc Natn Acad Sci U S A  85: 871–874.  <ul class="find" data-citedArticleID="1033198" data-doi="10.1073/pnas.85.3.871"><li><a href="http://dx.doi.org/10.1073/pnas.85.3.871" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Binding+of+photoreactive+lysozyme+peptides+to+murine+histocompatibility+class+II+molecules." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Binding+of+photoreactive+lysozyme+peptides+to+murine+histocompatibility+class+II+molecules.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">19.
              </span><a name="pone.0001348-Jensen2" id="pone.0001348-Jensen2"></a>Jensen PE (1990) Regulation of antigen presentation by acidic pH. J Exp Med  171: 779–1784.  <ul class="find" data-citedArticleID="1033188" data-doi="10.1084/jem.171.5.1779"><li><a href="http://dx.doi.org/10.1084/jem.171.5.1779" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Regulation+of+antigen+presentation+by+acidic+pH." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Regulation+of+antigen+presentation+by+acidic+pH.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">20.
              </span><a name="pone.0001348-Sallusto1" id="pone.0001348-Sallusto1"></a>Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med  179: 1109–1118.  <ul class="find" data-citedArticleID="1033218" data-doi="10.1084/jem.179.4.1109"><li><a href="http://dx.doi.org/10.1084/jem.179.4.1109" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Efficient+presentation+of+soluble+antigen+by+cultured+human+dendritic+cells+is+maintained+by+granulocyte%2Fmacrophage+colony-stimulating+factor+plus+interleukin+4+and+downregulated+by+tumor+necrosis+factor+%CE%B1." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Efficient+presentation+of+soluble+antigen+by+cultured+human+dendritic+cells+is+maintained+by+granulocyte%2Fmacrophage+colony-stimulating+factor+plus+interleukin+4+and+downregulated+by+tumor+necrosis+factor+%CE%B1.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">21.
              </span><a name="pone.0001348-Watts1" id="pone.0001348-Watts1"></a>Watts TH, McConneli HM (1986) High-affinity fluorescent peptide binding to I-Ad in lipid membranes. Proc Natn Acad Sci U S A  83: 9660–9664.  <ul class="find" data-citedArticleID="1033238" data-doi="10.1073/pnas.83.24.9660"><li><a href="http://dx.doi.org/10.1073/pnas.83.24.9660" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=High-affinity+fluorescent+peptide+binding+to+I-Ad+in+lipid+membranes." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22High-affinity+fluorescent+peptide+binding+to+I-Ad+in+lipid+membranes.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">22.
              </span><a name="pone.0001348-Cepellini1" id="pone.0001348-Cepellini1"></a>Cepellini R, Frumento G, Ferrara GB, Roberto T, Chersi A, et al.  (1989) Binding of labeled influenza matrix peptide to HLA DR in living B lymphoid cells. Nature  339: 392–394.  <ul class="find" data-citedArticleID="1033166" data-doi="10.1038/339392a0"><li><a href="http://dx.doi.org/10.1038/339392a0" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Binding+of+labeled+influenza+matrix+peptide+to+HLA+DR+in+living+B+lymphoid+cells." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Binding+of+labeled+influenza+matrix+peptide+to+HLA+DR+in+living+B+lymphoid+cells.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">23.
              </span><a name="pone.0001348-Theodore1" id="pone.0001348-Theodore1"></a>Theodore S, Jardetzky , Jeerry H, Brown , Joan C, et al.  (1996) Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc Natn Acad Sci U S A  93: 734–738.  <ul class="find" data-citedArticleID="1033234" data-doi="10.1073/pnas.93.2.734"><li><a href="http://dx.doi.org/10.1073/pnas.93.2.734" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Crystallographic+analysis+of+endogenous+peptides+associated+with+HLA-DR1+suggests+a+common%2C+polyproline+II-like+conformation+for+bound+peptides." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Crystallographic+analysis+of+endogenous+peptides+associated+with+HLA-DR1+suggests+a+common%2C+polyproline+II-like+conformation+for+bound+peptides.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">24.
              </span><a name="pone.0001348-Kai1" id="pone.0001348-Kai1"></a>Kai W, Wucherpfennig , Bei Y, Kailash B, Dimitri S, et al.  (1995) Structural basis for major histocompatibility complex (MHC)-like susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris. Proc Natn Acad Sci U S A  92: 11935–11939.  <ul class="find" data-citedArticleID="1033190" data-doi="10.1073/pnas.92.25.11935"><li><a href="http://dx.doi.org/10.1073/pnas.92.25.11935" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Structural+basis+for+major+histocompatibility+complex+%28MHC%29-like+susceptibility+to+autoimmunity%3A+charged+residues+of+a+single+MHC+binding+pocket+confer+selective+presentation+of+self-peptides+in+pemphigus+vulgaris." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Structural+basis+for+major+histocompatibility+complex+%28MHC%29-like+susceptibility+to+autoimmunity%3A+charged+residues+of+a+single+MHC+binding+pocket+confer+selective+presentation+of+self-peptides+in+pemphigus+vulgaris.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">25.
              </span><a name="pone.0001348-Morris1" id="pone.0001348-Morris1"></a>Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, et al.  (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem  19: 1639–1662.  <ul class="find" data-citedArticleID="1033210" data-doi="10.1002/(sici)1096-987x(19981115)19:14<1639::aid-jcc10&gt;3.0.co;2-b"><li><a href="http://dx.doi.org/10.1002/(sici)1096-987x(19981115)19:14<1639::aid-jcc10&gt;3.0.co;2-b" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Automated+docking+using+a+Lamarckian+genetic+algorithm+and+an+empirical+binding+free+energy+function." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Automated+docking+using+a+Lamarckian+genetic+algorithm+and+an+empirical+binding+free+energy+function.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">26.
              </span><a name="pone.0001348-Rammensee1" id="pone.0001348-Rammensee1"></a>Rammensee HG, FriedeT , Stevanovic S (1995) MHC ligands and peptide motifs: first listing. Immunogenetics  41: 178–228.  <ul class="find" data-citedArticleID="1033212" data-doi="10.1007/bf00172063"><li><a href="http://dx.doi.org/10.1007/bf00172063" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=MHC+ligands+and+peptide+motifs%3A+first+listing." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22MHC+ligands+and+peptide+motifs%3A+first+listing.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">27.
              </span><a name="pone.0001348-Grey1" id="pone.0001348-Grey1"></a>Grey HM, Chesnut R (1985) Antigen processing and presentation to T cells. Immunol Today  6: 101–105.  <ul class="find" data-citedArticleID="1033178" data-doi="10.1016/0167-5699(85)90025-8"><li><a href="http://dx.doi.org/10.1016/0167-5699(85)90025-8" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Antigen+processing+and+presentation+to+T+cells." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Antigen+processing+and+presentation+to+T+cells.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">28.
              </span><a name="pone.0001348-Masha2" id="pone.0001348-Masha2"></a>Masha HA, Dvora T, Evgeny G, Israel P, Chaim B, et al.  (1994) Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cellspecificity and promiscuity. Proc Nati Acad Sci U S A  91: 4872–4876.  <ul class="find" data-citedArticleID="1033202" data-doi="10.1073/pnas.91.11.4872"><li><a href="http://dx.doi.org/10.1073/pnas.91.11.4872" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Direct+binding+of+myelin+basic+protein+and+synthetic+copolymer+1+to+class+II+major+histocompatibility+complex+molecules+on+living+antigen-presenting+cellspecificity+and+promiscuity." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Direct+binding+of+myelin+basic+protein+and+synthetic+copolymer+1+to+class+II+major+histocompatibility+complex+molecules+on+living+antigen-presenting+cellspecificity+and+promiscuity.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">29.
              </span><a name="pone.0001348-Speck1" id="pone.0001348-Speck1"></a>Speck SH, Strominger JL (1987) Epstein-Barr virus transformation. Prog Nucleic Acid Res Mol Biol  34: 189–207.  <ul class="find" data-citedArticleID="1033228" data-doi="10.1016/s0079-6603(08)60496-1"><li><a href="http://dx.doi.org/10.1016/s0079-6603(08)60496-1" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Epstein-Barr+virus+transformation." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Epstein-Barr+virus+transformation.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">30.
              </span><a name="pone.0001348-Hammer1" id="pone.0001348-Hammer1"></a>Hammer J, Gallazzi F, Bono E, Karr RW, Guenot J, et al.  (1995) Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med  181: 1847–1855.  <ul class="find" data-citedArticleID="1033182" data-doi="10.1084/jem.181.5.1847"><li><a href="http://dx.doi.org/10.1084/jem.181.5.1847" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Peptide+binding+specificity+of+HLA-DR4+molecules%3A+correlation+with+rheumatoid+arthritis+association." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Peptide+binding+specificity+of+HLA-DR4+molecules%3A+correlation+with+rheumatoid+arthritis+association.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">31.
              </span><a name="pone.0001348-George1" id="pone.0001348-George1"></a>George AH, Tapan A, Daniel K, Goldstein G (1985) Structural requirements for the biological activity of thymopentin analogs. Archs Biochem Biophysics  242: 248–255.  <ul class="find" data-citedArticleID="1033174" data-doi="10.1016/0003-9861(85)90499-0"><li><a href="http://dx.doi.org/10.1016/0003-9861(85)90499-0" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Structural+requirements+for+the+biological+activity+of+thymopentin+analogs." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Structural+requirements+for+the+biological+activity+of+thymopentin+analogs.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">32.
              </span><a name="pone.0001348-Tara1" id="pone.0001348-Tara1"></a>Tara MCH, Shiloh MM, Nancy BM, Janet MC (2001) Peptide length variants p2Ca and QL9 present distinct conformations to L<sup>d</sup>-specific T cells. J Immunol  167: 4207–4214.  <ul class="find" data-citedArticleID="1033232"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=Peptide+length+variants+p2Ca+and+QL9+present+distinct+conformations+to+Ld-specific+T+cells.&amp;auth=&amp;atitle=Peptide+length+variants+p2Ca+and+QL9+present+distinct+conformations+to+Ld-specific+T+cells." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Peptide+length+variants+p2Ca+and+QL9+present+distinct+conformations+to+Ld-specific+T+cells." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Peptide+length+variants+p2Ca+and+QL9+present+distinct+conformations+to+Ld-specific+T+cells.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">33.
              </span><a name="pone.0001348-Bouvier1" id="pone.0001348-Bouvier1"></a>Bouvier M, Guo HC, Smith KJ, Wiley DC (1998) Crystal structures of HLA-A*0201 complexed with either the amino- or carboxyl-terminal group substituted by a methyl group. Proteins  33: 97–106.  <ul class="find" data-citedArticleID="1033162" data-doi="10.1002/(sici)1097-0134(19981001)33:1<97::aid-prot9&gt;3.0.co;2-i"><li><a href="http://dx.doi.org/10.1002/(sici)1097-0134(19981001)33:1<97::aid-prot9&gt;3.0.co;2-i" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Crystal+structures+of+HLA-A*0201+complexed+with+either+the+amino-+or+carboxyl-terminal+group+substituted+by+a+methyl+group." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Crystal+structures+of+HLA-A*0201+complexed+with+either+the+amino-+or+carboxyl-terminal+group+substituted+by+a+methyl+group.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">34.
              </span><a name="pone.0001348-McFarland1" id="pone.0001348-McFarland1"></a>McFarland BJ, Sant AJ, Lybrand TP, Beesona C (1999) Ovalbumin (323–339) peptide binds to the major histocompatibility complex class II I-A<sup>d</sup> protein using two functionally distinct registers. Biochemistry  38: 16663–16670.  <ul class="find" data-citedArticleID="1033204" data-doi="10.1021/bi991393l"><li><a href="http://dx.doi.org/10.1021/bi991393l" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Ovalbumin+%28323%E2%80%93339%29+peptide+binds+to+the+major+histocompatibility+complex+class+II+I-Ad+protein+using+two+functionally+distinct+registers." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Ovalbumin+%28323%E2%80%93339%29+peptide+binds+to+the+major+histocompatibility+complex+class+II+I-Ad+protein+using+two+functionally+distinct+registers.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">35.
              </span><a name="pone.0001348-Robertson1" id="pone.0001348-Robertson1"></a>Robertson JM, Jensen PE, Evavold BD (2000) DO11.10 and OT-II T cells recognize a C-terminal ovalbumin 323–339 epitope. J Immunol  164: 4706–4712.  <ul class="find" data-citedArticleID="1033216"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=DO11.10+and+OT-II+T+cells+recognize+a+C-terminal+ovalbumin+323%3F339+epitope.&amp;auth=&amp;atitle=DO11.10+and+OT-II+T+cells+recognize+a+C-terminal+ovalbumin+323%3F339+epitope." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=DO11.10+and+OT-II+T+cells+recognize+a+C-terminal+ovalbumin+323%E2%80%93339+epitope." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22DO11.10+and+OT-II+T+cells+recognize+a+C-terminal+ovalbumin+323%E2%80%93339+epitope.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">36.
              </span><a name="pone.0001348-Merrifield1" id="pone.0001348-Merrifield1"></a>Merrifield RB (1963) Solid Phase peptide synthesis. The synthesis of a tetrapeptide. J Am Chem Soc  85: 2149–2154.  <ul class="find" data-citedArticleID="1033208" data-doi="10.1021/ja00897a025"><li><a href="http://dx.doi.org/10.1021/ja00897a025" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Solid+Phase+peptide+synthesis.+The+synthesis+of+a+tetrapeptide." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Solid+Phase+peptide+synthesis.+The+synthesis+of+a+tetrapeptide.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">37.
              </span><a name="pone.0001348-Arvinte1" id="pone.0001348-Arvinte1"></a>Arvinte T, Cudd A, Drake AF (1993) The structure and mechanism of human calcitonin fibrils. J Biol Chem  268: 6415–6422.  <ul class="find" data-citedArticleID="1033156"><li><a href="http://www.crossref.org/guestquery/?auth2=&amp;atitle2=The+structure+and+mechanism+of+human+calcitonin+fibrils.&amp;auth=&amp;atitle=The+structure+and+mechanism+of+human+calcitonin+fibrils." target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=The+structure+and+mechanism+of+human+calcitonin+fibrils." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22The+structure+and+mechanism+of+human+calcitonin+fibrils.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">38.
              </span><a name="pone.0001348-Feig1" id="pone.0001348-Feig1"></a>Feig M, John K, Charles L (2004) Brooks III: MMTSB tool set: enhanced sampling and multiscale modeling methods for applications in structural biology. J Mol Graphics Modell  22: 377–395.  <ul class="find" data-citedArticleID="1033172" data-doi="10.1016/j.jmgm.2003.12.005"><li><a href="http://dx.doi.org/10.1016/j.jmgm.2003.12.005" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Brooks+III%3A+MMTSB+tool+set%3A+enhanced+sampling+and+multiscale+modeling+methods+for+applications+in+structural+biology." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Brooks+III%3A+MMTSB+tool+set%3A+enhanced+sampling+and+multiscale+modeling+methods+for+applications+in+structural+biology.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">39.
              </span><a name="pone.0001348-Mehler1" id="pone.0001348-Mehler1"></a>Mehler EL, Solmajer T (1991) Electrostatic effects in proteins: comparison of dielectric and charge models. Protein Eng  4: 903–910.  <ul class="find" data-citedArticleID="1033206" data-doi="10.1093/protein/4.8.903"><li><a href="http://dx.doi.org/10.1093/protein/4.8.903" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=Electrostatic+effects+in+proteins%3A+comparison+of+dielectric+and+charge+models." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22Electrostatic+effects+in+proteins%3A+comparison+of+dielectric+and+charge+models.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">40.
              </span><a name="pone.0001348-Liu1" id="pone.0001348-Liu1"></a>Liu S, Zhang C, Zhou H, Zhou Y (2004) A physical reference state unifies the structure-derived potential of mean force for protein folding and binding. Proteins  56: 93–101.  <ul class="find" data-citedArticleID="1033196" data-doi="10.1002/prot.20019"><li><a href="http://dx.doi.org/10.1002/prot.20019" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=A+physical+reference+state+unifies+the+structure-derived+potential+of+mean+force+for+protein+folding+and+binding." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22A+physical+reference+state+unifies+the+structure-derived+potential+of+mean+force+for+protein+folding+and+binding.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li><li><span class="label">41.
              </span><a name="pone.0001348-DeLano1" id="pone.0001348-DeLano1"></a>DeLano WL (2002) The PyMOL molecular graphics system. San Carlos, CA, USA: DeLano Scientific.   Available: http:// <a href="http://www.pymol.org">www.pymol.org</a>.  <ul class="find-nolinks"></ul></li><li><span class="label">42.
              </span><a name="pone.0001348-Wallace1" id="pone.0001348-Wallace1"></a>Wallace AC, Laskowski RA, Thornton JM (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Prot Eng  8: 127–134.  <ul class="find" data-citedArticleID="1033236" data-doi="10.1093/protein/8.2.127"><li><a href="http://dx.doi.org/10.1093/protein/8.2.127" target="_new" title="Go to article in CrossRef">
                          View Article
                        </a></li><li><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Search&amp;doptcmdl=Citation&amp;defaultField=Title+Word&amp;term=LIGPLOT%3A+a+program+to+generate+schematic+diagrams+of+protein-ligand+interactions." target="_new" title="Go to article in PubMed">
                          PubMed/NCBI
                        </a></li><li><a href="http://scholar.google.com/scholar?hl=en&amp;safe=off&amp;q=%22LIGPLOT%3A+a+program+to+generate+schematic+diagrams+of+protein-ligand+interactions.%22" target="_new" title="Go to article in Google Scholar">
                          Google Scholar
                        </a></li></ul></li></ol></div>

  </div>

      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.XML" value="80041"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.PDF" value="466507"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g001.PNG_L" value="2866966"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g001.PNG_M" value="100140"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g001.PNG_S" value="4712"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g001.TIF" value="3720732"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g001.PNG_I" value="28987"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g002.PNG_L" value="27466"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g002.PNG_M" value="23574"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g002.PNG_S" value="5700"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g002.TIF" value="56942"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g002.PNG_I" value="8634"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g003.PNG_L" value="19564"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g003.PNG_M" value="24386"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g003.PNG_S" value="5798"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g003.TIF" value="35824"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g003.PNG_I" value="8961"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g004.PNG_L" value="270108"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g004.PNG_M" value="74134"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g004.PNG_S" value="11044"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g004.TIF" value="1071038"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g005.PNG_L" value="95096"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g005.PNG_M" value="22085"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g005.PNG_S" value="7543"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g005.TIF" value="218172"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g005.PNG_I" value="7107"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t001.PNG_L" value="64238"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t001.PNG_M" value="83479"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t001.PNG_S" value="13296"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t001.TIF" value="295912"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t001.PNG_I" value="28688"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g006.PNG_L" value="2019108"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g006.PNG_M" value="398359"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g006.PNG_S" value="25444"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g006.TIF" value="3263182"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g006.PNG_I" value="207852"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t002.PNG_L" value="42537"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t002.PNG_M" value="51036"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t002.PNG_S" value="10463"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t002.TIF" value="208082"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t002.PNG_I" value="17019"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t003.PNG_L" value="34684"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t003.PNG_M" value="43027"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t003.PNG_S" value="9487"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t003.TIF" value="162848"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.t003.PNG_I" value="14166"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g007.PNG_L" value="2522486"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g007.PNG_M" value="281459"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g007.PNG_S" value="20615"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g007.TIF" value="3519516"/>
      <input type="hidden" class="assetSize" name="info:doi/10.1371/journal.pone.0001348.g007.PNG_I" value="94671"/>

</div>
<div class="sidebar">

  <div class="article-actions cf">
      <div class="download">
        <span class="btn"><a href="/article/fetchObject.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0001348&amp;representation=PDF" title="Download" target="_blank">Download PDF</a></span>
      </div>
      <div class="btn-reveal dropdown">
        <div class="dropdown-icon">
          <span class="btn">&nbsp;</span>
        </div>

        <div class="content">
          <ul class="bullet">
            <li><a href="/article/citationList.action?articleURI=info%3Adoi%2F10.1371%2Fjournal.pone.0001348" title="Download citations">Citation</a></li>
            <li><a href="/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0001348&amp;representation=XML" title="Download article XML">XML</a></li>
          </ul>
        </div>
      </div> <!-- end btn-reveal dropdown-->


    <div class="btn-reveal flt-l">
        <span class="btn">Print</span>
        <div class="content">
            <ul class="bullet">
                <li id="print-article"><a href="#" onclick="if(typeof(_gaq) != 'undefined'){ _gaq.push(['_trackEvent','Article', 'Print', 'Click']); } window.print(); return false;" title="Print Article">Print article</a></li>
                <li>
                  <a href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=7&doi=10.1371/journal.pone.0001348&volume=&issue=&title=Molecular Analysis of Thymopentin Binding to HLA-DR Molecules&author_name=Zuojia%20Liu%2C%20Xiliang%20Zheng%2C%20Jin%20Wang%2C%20Erkang%20Wang&start_page=1&end_page=8" title="Odyssey Press">EzReprint</a>
                </li>
            </ul>
        </div>
    </div>

    <div class="btn-reveal flt-r">
        <span class="btn">Share</span>
        <div class="content">
            <ul class="social">
                <li><a href="http://www.reddit.com/submit?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001348" target="_blank" title="Submit to Reddit"><img src="/images/icon.reddit.16.png" width="16" height="16" alt="Reddit">Reddit</a></li>

                <li><a href="https://plus.google.com/share?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001348" target="_blank" title="Share on Google+"><img src="/images/icon.gplus.16.png" width="16" height="16" alt="Google+">Google+</a></li>

                <li><a href="http://www.stumbleupon.com/submit?url=http%3A%2F%2Fwww.plosone.org%2Farticle%2Finfo%253Adoi%252F10.1371%252Fjournal.pone.0001348" target="_blank" title="Add to StumbleUpon"><img src="/images/icon.stumble.16.png" width="16" height="16" alt="StumbleUpon">StumbleUpon</a></li>

                <li><a href="http://www.facebook.com/share.php?u=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001348&amp;t=Molecular%20Analysis%20of%20Thymopentin%20Binding%20to%20HLA-DR%20Molecules" target="_blank" title="Share on Facebook"><img src="/images/icon.fb.16.png" width="16" height="16" alt="Facebook">Facebook</a></li>

                <li><a href="http://www.linkedin.com/shareArticle?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001348&title=Molecular%20Analysis%20of%20Thymopentin%20Binding%20to%20HLA-DR%20Molecules&summary=Checkout%20this%20article%20I%20found%20at%20PLOS" target="_blank" title="Add to LinkedIn"><img src="/images/icon.linkedin.16.png" width="16" height="16" alt="Mendeley">LinkedIn</a></li>

                <li><a href="http://www.citeulike.org/posturl?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001348&amp;title=Molecular%20Analysis%20of%20Thymopentin%20Binding%20to%20HLA-DR%20Molecules" target="_blank" title="Add to CiteULike"><img src="/images/icon.cul.16.png" width="16" height="16" alt="CiteULike">CiteULike</a></li>

                <li><a href="http://www.mendeley.com/import/?url=http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001348" target="_blank" title="Add to Mendeley"><img src="/images/icon.mendeley.16.png" width="16" height="16" alt="Mendeley">Mendeley</a></li>

                <li><a href="https://www.pubchase.com/library?add_aid=10.1371%2Fjournal.pone.0001348&amp;source=plos" target="_blank" title="Add to PubChase"><img src="/images/icon.pc.16.png" width="16" height="16" alt="PubChase">PubChase</a></li>


                <script type="text/javascript">
                    // replace tweet with one that's pre-shortened to 140 chars
                    function truncateTweetText() {
                        var twtTitle = 'Molecular Analysis of Thymopentin Binding to HLA-DR Molecules';
                        var twtUrl = 'http://dx.plos.org/10.1371/journal.pone.0001348';
                        // all URLs posted to twitter get auto-shortened to 20 chars.
                        var maxLength = 140 - (20 + 1);
                        // truncate the title to include space for twtTag and ellipsis (here, 10 = tag length + space + ellipsis)
                        if (twtTitle.length > maxLength) { twtTitle = twtTitle.substr(0, (maxLength - 10)) + '...'; }
                        // set the href to use the shortened tweet
                        $('#twitter-share-link').prop('href', 'http://twitter.com/intent/tweet?text=' + encodeURIComponent('#PLOSONE: ' + twtTitle + ' ' + twtUrl));
                    }
                </script>
                <li><a href="http://twitter.com/intent/tweet?text=#PLOSONE%3A%20Molecular%20Analysis%20of%20Thymopentin%20Binding%20to%20HLA-DR%20Molecules http%3A%2F%2Fdx.plos.org%2F10.1371%2Fjournal.pone.0001348" onclick="truncateTweetText();" target="_blank" title="Share on Twitter" id="twitter-share-link"><img src="/images/icon.twtr.16.png" width="16" height="16" alt="Twitter">Twitter</a></li>

                <li><a href="/article/email/info%3Adoi%2F10.1371%2Fjournal.pone.0001348" title="Email this article"><img src="/images/icon.email.16.png" width="16" height="16" alt="Email">Email</a></li>
            </ul>
        </div>
    </div><!--end btn-reveal flt-r-->
</div><!-- end article-actions-->

<!-- begin Crossmark -->

<a id="open-crossmark" href="#" style="margin-top: -28px; display:block"><img style="border: 0; display: none;
 padding: 10px 0 18px 0;"  id="crossmark-icon" src="/images/logo-crossmark-bw.png" /></a>
<div id="crossmark-dialog" style="display: none;" title="">
    <!-- the external CrossMark data is loaded inside this iframe -->
    <iframe id="crossmark-dialog-frame" frameborder="0"></iframe>
</div>

<!-- end crossmark -->


<div class="block" id="subject-area-sidebar-block">
    <div class="header">
        <h3>Subject Areas</h3><div title="More information" id="subject-area-sidebar-block-help-icon"><img align="right"
                                                                                                           alt="info" src="/images/button_info.png"/><div id="subject-area-sidebar-block-help"><img align="right"
                                                                                                                                                                                                    src="/images/button_info.png"/><p>
        <b>We want your feedback.</b> Do these subject areas make sense for this article? If not, click the flag
        next to the incorrect subject area and we will review it. Thanks for your help!
    </p></div></div>
    </div>


    <ul id="subject-area-sidebar-list">



















          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Alanine%22" title="Search for articles in the subject area:'Alanine'"><div class="flagText">Alanine</div></a>
              <div data-categoryid="40577" data-articleid="25526"
                   data-categoryname="Alanine"
                   class="flagImage" title="Flag 'Alanine' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22B+cells%22" title="Search for articles in the subject area:'B cells'"><div class="flagText">B cells</div></a>
              <div data-categoryid="31979" data-articleid="25526"
                   data-categoryname="B cells"
                   class="flagImage" title="Flag 'B cells' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Binding+analysis%22" title="Search for articles in the subject area:'Binding analysis'"><div class="flagText">Binding analysis</div></a>
              <div data-categoryid="19597" data-articleid="25526"
                   data-categoryname="Binding analysis"
                   class="flagImage" title="Flag 'Binding analysis' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Cell+binding%22" title="Search for articles in the subject area:'Cell binding'"><div class="flagText">Cell binding</div></a>
              <div data-categoryid="19609" data-articleid="25526"
                   data-categoryname="Cell binding"
                   class="flagImage" title="Flag 'Cell binding' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Cell+binding+assay%22" title="Search for articles in the subject area:'Cell binding assay'"><div class="flagText">Cell binding assay</div></a>
              <div data-categoryid="20085" data-articleid="25526"
                   data-categoryname="Cell binding assay"
                   class="flagImage" title="Flag 'Cell binding assay' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Fluorescence+competition%22" title="Search for articles in the subject area:'Fluorescence competition'"><div class="flagText">Fluorescence competition</div></a>
              <div data-categoryid="23197" data-articleid="25526"
                   data-categoryname="Fluorescence competition"
                   class="flagImage" title="Flag 'Fluorescence competition' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22Free+energy%22" title="Search for articles in the subject area:'Free energy'"><div class="flagText">Free energy</div></a>
              <div data-categoryid="18159" data-articleid="25526"
                   data-categoryname="Free energy"
                   class="flagImage" title="Flag 'Free energy' as inappropriate"></div>
          </li>
          <li>
              <a href="/search/advanced?unformattedQuery=subject%3A%22T+cells%22" title="Search for articles in the subject area:'T cells'"><div class="flagText">T cells</div></a>
              <div data-categoryid="40147" data-articleid="25526"
                   data-categoryname="T cells"
                   class="flagImage" title="Flag 'T cells' as inappropriate"></div>
          </li>
    </ul>
</div>

<div class="ad">
    <div class="title">Advertisement</div>






  <iframe id='a0852f54' name='a0852f54'
    src='http://ads.plos.org/www/delivery/afr.php?zoneid=381&amp;cb=3571'
    frameborder='0' scrolling='no' width='160' height='600'>
    <a href='http://ads.plos.org/www/delivery/ck.php?n=a0852f54&amp;cb=9474'
      target='_top'><img src='http://ads.plos.org/www/delivery/avw.php?zoneid=381&amp;cb=511&amp;n=a0852f54'
      border='0' alt=''/>
    </a>
  </iframe>



</div>

<div id="twitter-alm-timeline" class="twitter-alm-timeline"></div>

<div class="block sidebar-comments">
    <div class="header">
        <h3>Comments</h3>
    </div>
      <p><a href="/annotation/listThread.action?root=7801">Unconvincing data</a><br>Posted by rotzschke</p>
</div>

</div><!-- sidebar -->
    </div>
  </div>
</div>
<script src="http://wl.figshare.com/static/p_widget.js" type="text/javascript"></script><div id="pageftr">
  <div class="ftr-cols cf">
    <div class="col col-1">
      <img src="/images/logo-plos-footer.png" alt="PLOS Logo" class="logo" />
      <p><a href="/static/releaseNotes">Ambra 2.9.16</a> Managed Colocation provided <br />by <a href="http://www.isc.org/">Internet Systems Consortium</a>.<p>
      <div class="nav nav-aux">
        <a href="/static/privacy">Privacy Policy</a> |
        <a href="/static/terms">Terms of Use</a> |
        <a href="http://www.plos.org/advertise/">Advertise</a> |
        <a href="http://www.plos.org/about/media-inquiries/">Media Inquiries</a>
      </div>
    </div>
    <div class="col col-2">
      <p><a href="http://www.plos.org/publications/journals/">Publications</a></p>
      <div class="nav">
        <ul>
          <li><a href="http://www.plosbiology.org">PLOS Biology</a></li>
          <li><a href="http://www.plosmedicine.org">PLOS Medicine</a></li>
          <li><a href="http://www.ploscompbiol.org">PLOS Computational Biology</a></li>
          <li><a href="http://currents.plos.org">PLOS Currents</a></li>
          <li><a href="http://www.plosgenetics.org">PLOS Genetics</a></li>
          <li><a href="http://www.plospathogens.org">PLOS Pathogens</a></li>
          <li><a href="http://www.plosone.org">PLOS ONE</a></li>
          <li><a href="http://www.plosntds.org">PLOS Neglected Tropical Diseases</a></li>
        </ul>
      </div>
    </div>
    <div class="col col-3">
      <div class="nav">
        <p><a href="http://www.plos.org">plos.org</a></p>
        <p><a href="http://blogs.plos.org">Blogs</a></p>
        <p><a href="http://www.ploscollections.org">Collections</a></p>
        <p><a href="/feedback/new">Send us feedback</a></p>

        <p>California (US) corporation #C2354500, based in San Francisco</p>
      </div>
    </div>
  </div>
</div><!-- pageftr -->

</div><!-- end page-wrap, this div is in header.ftl -->
<script type="text/javascript" src="/javascript/jquery-1.8.1-min.js?v=Tm7VCOzZz3lE03ghpkS6SWkHbyI"></script>
<script type="text/javascript" src="/javascript/ga-min.js?v=lNQ4gt8QcPDatjsdOFl_FGpPhLY"></script>
<script type="text/javascript" src="/javascript/jquery.hoverIntent-min.js?v=mRiGNYY9cIXxVb8u0K_MdW7hHnc"></script>
<script type="text/javascript" src="/javascript/jquery.placeholder-min.js?v=21Pn56Ur9h1N4K4VZDa0nqI3Pxo"></script>
<script type="text/javascript" src="/javascript/jquery.jsonp-2.4.0-min.js?v=lqTpzoHfSq3I5Ygo01qq5WankEo"></script>
<script type="text/javascript" src="/javascript/jquery-ui-1.9.2.custom-min.js?v=raSSlfNO0YsV5uUpAKmTB9n5VTc"></script>
<script type="text/javascript" src="/javascript/jquery.tooltip-min.js?v=cw+6Smh+mdryIA25xvqIvHMrnZM"></script>
<script type="text/javascript" src="/javascript/jquery.uniform-min.js?v=kYUAnX6W2W_2fK3RIuQ2m_YFG9U"></script>
<script type="text/javascript" src="/javascript/jquery.pjax-min.js?v=939kLBjL5_YKbx71T1RHjYaD4l8"></script>
<script type="text/javascript" src="/javascript/imagesloaded-min.js?v=XeuAp8Gc3mvQUo+wZCSF8ttPwvw"></script>
<script type="text/javascript" src="/javascript/figviewer-min.js?v=yPUa0sUQ_iHkI+IRv2i9bjyZJFo"></script>
<script type="text/javascript" src="/javascript/global-min.js?v=0Q3PwjeaWtXYDnqIsQvnL_ou0qs"></script>
<script type="text/javascript" src="/javascript/jquery.touchswipe-min.js?v=huaek_e6HqTduvCNAN91dJolTyw"></script>
<script type="text/javascript" src="/javascript/jquery.base64-min.js?v=VwV1zeVqKZj5FCAdlK0q5NRxbBg"></script>
<script type="text/javascript" src="/javascript/alm-min.js?v=Y5gm6B0b4Kx2YHNObNrgEeBgXlY"></script>
<script type="text/javascript" src="/javascript/taxonomy-browser-min.js?v=vBVMuDMYkGJCXIUxLe35GoyiJNw"></script>
<script type="text/javascript" src="/javascript/jquery.filterize-min.js?v=j0ZKVnHyk2nhFy8eIuNJkp7xaM0"></script>
<script type="text/javascript" src="/javascript/plosone-min.js?v=TK4H4arL_XBSwwJq+K1N3kqYfAI"></script>
<script type="text/javascript" src="/javascript/twitter-min.js?v=xKgcxLsQFXy+at1ao1NVke8nFlM"></script>
<script type="text/javascript" src="/javascript/crossmark.1.4-min.js?v=3FO4k0SjwTaGNnKGNSqthar1080"></script>
<script type="text/javascript">
  var _sf_async_config={uid:16579,domain:"plosone.org"};
  (function(){
    function loadChartbeat() {
      window._sf_endpt=(new Date()).getTime();
      var e = document.createElement('script');
      e.setAttribute('language', 'javascript');
      e.setAttribute('type', 'text/javascript');
      e.setAttribute('src',
          (("https:" == document.location.protocol) ? "https://a248.e.akamai.net/chartbeat.download.akamai.com/102508/" : "http://static.chartbeat.com/") +
              "js/chartbeat.js");
      document.body.appendChild(e);
    }
    var oldonload = window.onload;
    window.onload = (typeof window.onload != 'function') ?
        loadChartbeat : function() { oldonload(); loadChartbeat(); };
  })();
</script>
<!-- <script type="application/javascript" src="http://crossmark.crossref.org/javascripts/v1.3/crossmark.min.js"></script> -->

</body>
</html>
